- Published on
Emergency and Acute Medicine – Central Retinal Artery Occlusion
Overview
Central retinal artery occlusion (CRAO) is an obstruction of the central retinal artery resulting in sudden, painless, monocular vision loss. It typically affects adults aged 50–70 years and is often described as a “stroke of the eye.” The ophthalmic artery is the first branch of the carotid artery. Risk factors include hypertension, atherosclerosis, carotid artery disease, valvular heart disease, coronary artery disease, vasculitis, lupus, sickle cell disease, and trauma. Incidence is approximately 1–10 per 100,000. Irreversible retinal injury can occur within 90 minutes.
Causative Mechanisms
Embolic causes are most common and include cholesterol or platelet emboli from carotid atherosclerosis, carotid stenosis, valvular heart disease, atrial myxoma, or arterial dissection. Thrombotic causes result from rupture of an atherosclerotic plaque or hypercoagulable states such as sickle cell disease. Inflammatory causes include giant cell arteritis, lupus, and systemic vasculitis. Arterial spasm may be migraine-related. Reduced ocular perfusion may occur with severe hypotension, acute angle-closure glaucoma, or retrobulbar hemorrhage.
Clinical Presentation
Patients present with sudden, painless, unilateral vision loss. Some report prior transient episodes of visual loss lasting seconds to minutes (amaurosis fugax). Visual acuity is markedly reduced. An afferent pupillary defect is usually present. Fundoscopy may reveal emboli within retinal vessels appearing as yellow-white glistening plaques, ischemic retinal edema within 15–20 minutes, and a classic cherry-red spot at the fovea. Retinal arteries may appear empty or show segmented “box-carring.” Within 1–2 hours, the infarcted retina becomes opaque. Partial visual field deficits suggest branch retinal artery involvement.
Essential Evaluation
Immediate assessment includes visual acuity, visual fields, fundoscopic examination, intraocular pressure measurement, and urgent ophthalmology consultation.
Diagnostic Studies
Laboratory evaluation targets underlying causes and includes CBC with platelets, PT/PTT, electrolytes, renal function, glucose, ESR and CRP (especially in patients >55 years for giant cell arteritis), ANA, RF, RPR, hemoglobin electrophoresis, and serum protein electrophoresis. Imaging focuses on embolic sources and includes carotid Doppler ultrasound and echocardiography. Fluorescein angiography or electroretinography may confirm diagnosis.
Differential Considerations
Acute angle-closure glaucoma, central retinal vein occlusion, giant cell arteritis, optic neuritis, and retinal detachment.
Emergency Management Principles
This is a true ophthalmologic emergency. Treatment must begin immediately to attempt retinal salvage. Goals include embolus displacement or dissolution, vasodilation to improve retinal perfusion, and reduction of intraocular pressure to enhance the perfusion gradient.
Emergency Department Interventions
Initiate immediate ocular (global) massage with the patient supine: apply firm pressure on the closed eyelid for 15 seconds, release for 15 seconds, and repeat for five cycles. Administer 100% oxygen via nonrebreather mask and consider hyperbaric oxygen if within 24 hours of onset. Carbogen inhalation may be used if available. Reduce intraocular pressure with IV acetazolamide and topical timolol. Administer aspirin and IV heparin to prevent clot propagation. Obtain emergent ophthalmology consultation for possible anterior chamber paracentesis and consideration of intra-arterial fibrinolysis. If inflammatory arteritis is suspected, begin high-dose systemic corticosteroids immediately.
Medications
First-line options include acetazolamide 500 mg IV or PO, timolol maleate 0.5% ophthalmic drops, IV heparin (80 U/kg bolus then 18 U/kg/hr infusion), and carbogen inhalation. Second-line or adjunctive therapies include aspirin 325 mg PO, methylprednisolone 250 mg IV for suspected arteritis, mannitol, and sublingual nitroglycerin.
Disposition and Follow-Up
Most acute cases require admission for urgent evaluation of embolic, thrombotic, or inflammatory sources. Chronic or remote occlusions without active disease may be evaluated outpatient. All suspected cases require immediate ophthalmology involvement. Carotid imaging is recommended in most patients.
Clinical Insights and Pitfalls
Transient monocular vision loss (amaurosis fugax) is a warning sign for CRAO and systemic stroke and requires urgent evaluation. CRAO is a medical and ophthalmologic emergency with a very narrow therapeutic window. Thorough documentation of visual acuity and fundoscopic findings is essential.
Overview
Central retinal artery occlusion (CRAO) is an obstruction of the central retinal artery resulting in sudden, painless, monocular vision loss. It typically affects adults aged 50–70 years and is often described as a “stroke of the eye.” The ophthalmic artery is the first branch of the carotid artery. Risk factors include hypertension, atherosclerosis, carotid artery disease, valvular heart disease, coronary artery disease, vasculitis, lupus, sickle cell disease, and trauma. Incidence is approximately 1–10 per 100,000. Irreversible retinal injury can occur within 90 minutes.
Causative Mechanisms
Embolic causes are most common and include cholesterol or platelet emboli from carotid atherosclerosis, carotid stenosis, valvular heart disease, atrial myxoma, or arterial dissection. Thrombotic causes result from rupture of an atherosclerotic plaque or hypercoagulable states such as sickle cell disease. Inflammatory causes include giant cell arteritis, lupus, and systemic vasculitis. Arterial spasm may be migraine-related. Reduced ocular perfusion may occur with severe hypotension, acute angle-closure glaucoma, or retrobulbar hemorrhage.
Clinical Presentation
Patients present with sudden, painless, unilateral vision loss. Some report prior transient episodes of visual loss lasting seconds to minutes (amaurosis fugax). Visual acuity is markedly reduced. An afferent pupillary defect is usually present. Fundoscopy may reveal emboli within retinal vessels appearing as yellow-white glistening plaques, ischemic retinal edema within 15–20 minutes, and a classic cherry-red spot at the fovea. Retinal arteries may appear empty or show segmented “box-carring.” Within 1–2 hours, the infarcted retina becomes opaque. Partial visual field deficits suggest branch retinal artery involvement.
Essential Evaluation
Immediate assessment includes visual acuity, visual fields, fundoscopic examination, intraocular pressure measurement, and urgent ophthalmology consultation.
Diagnostic Studies
Laboratory evaluation targets underlying causes and includes CBC with platelets, PT/PTT, electrolytes, renal function, glucose, ESR and CRP (especially in patients >55 years for giant cell arteritis), ANA, RF, RPR, hemoglobin electrophoresis, and serum protein electrophoresis. Imaging focuses on embolic sources and includes carotid Doppler ultrasound and echocardiography. Fluorescein angiography or electroretinography may confirm diagnosis.
Differential Considerations
Acute angle-closure glaucoma, central retinal vein occlusion, giant cell arteritis, optic neuritis, and retinal detachment.
Emergency Management Principles
This is a true ophthalmologic emergency. Treatment must begin immediately to attempt retinal salvage. Goals include embolus displacement or dissolution, vasodilation to improve retinal perfusion, and reduction of intraocular pressure to enhance the perfusion gradient.
Emergency Department Interventions
Initiate immediate ocular (global) massage with the patient supine: apply firm pressure on the closed eyelid for 15 seconds, release for 15 seconds, and repeat for five cycles. Administer 100% oxygen via nonrebreather mask and consider hyperbaric oxygen if within 24 hours of onset. Carbogen inhalation may be used if available. Reduce intraocular pressure with IV acetazolamide and topical timolol. Administer aspirin and IV heparin to prevent clot propagation. Obtain emergent ophthalmology consultation for possible anterior chamber paracentesis and consideration of intra-arterial fibrinolysis. If inflammatory arteritis is suspected, begin high-dose systemic corticosteroids immediately.
Medications
First-line options include acetazolamide 500 mg IV or PO, timolol maleate 0.5% ophthalmic drops, IV heparin (80 U/kg bolus then 18 U/kg/hr infusion), and carbogen inhalation. Second-line or adjunctive therapies include aspirin 325 mg PO, methylprednisolone 250 mg IV for suspected arteritis, mannitol, and sublingual nitroglycerin.
Disposition and Follow-Up
Most acute cases require admission for urgent evaluation of embolic, thrombotic, or inflammatory sources. Chronic or remote occlusions without active disease may be evaluated outpatient. All suspected cases require immediate ophthalmology involvement. Carotid imaging is recommended in most patients.
Clinical Insights and Pitfalls
Transient monocular vision loss (amaurosis fugax) is a warning sign for CRAO and systemic stroke and requires urgent evaluation. CRAO is a medical and ophthalmologic emergency with a very narrow therapeutic window. Thorough documentation of visual acuity and fundoscopic findings is essential.
- Published on
Emergency and Acute Medicine – Central Retinal Vein Occlusion
Overview
Central retinal vein occlusion (CRVO) is characterized by decreased visual acuity due to venous outflow obstruction of the retina. Vision loss is typically acute, unilateral, and painless. The condition results from impaired venous drainage leading to retinal hemorrhage, edema, and ischemia.
Pathophysiologic Types
Ischemic CRVO accounts for approximately 20–25% of cases and represents complete venous obstruction. Blocked venous return causes capillary backflow, extensive hemorrhage, macular edema, and retinal ischemia. Thrombosis is promoted by limited space at the lamina cribrosa, slow blood flow, vessel wall changes, adjacent arteriosclerotic arterial compression, and increased blood viscosity.
Nonischemic CRVO represents partial or incomplete occlusion and is generally milder with better visual prognosis.
Clinical Features
Patients present with acute, painless, unilateral loss of vision. In nonischemic CRVO, vision loss may be intermittent or incomplete. Visual acuity is often severely reduced, commonly worse than 20/200. An afferent pupillary defect may be present. Fundoscopic examination reveals dilated and tortuous retinal veins, widespread retinal hemorrhages involving all four quadrants in central involvement, optic disc edema, and cotton wool spots. Extensive hemorrhage produces the classic “blood and thunder” appearance.
Essential Assessment
Measure blood pressure. Perform visual acuity testing, visual field assessment, fundoscopy, and tonometry. Normal intraocular pressure ranges from 10–21 mm Hg.
Diagnostic Evaluation
Laboratory studies include CBC, PT/PTT, ESR, ANA, and serum protein electrophoresis to assess for systemic or hyperviscosity conditions. Fluorescein angiography, performed by ophthalmology, differentiates ischemic from nonischemic CRVO by identifying areas of capillary nonperfusion. Gonioscopy is used to evaluate for iris or angle neovascularization.
Differential Considerations
Amaurosis fugax or TIA, cavernous sinus thrombosis, diabetic or hypertensive retinopathy, hyperviscosity syndromes (sickle cell disease, polycythemia, leukemia, multiple myeloma), ocular ischemia syndrome, papilledema, retinal artery occlusion, retinal detachment, temporal arteritis, vitreous hemorrhage, severe anemia with thrombocytopenia, and functional vision loss.
Initial Management Principles
There are no prehospital eye-specific interventions. In the ED, address elevated intraocular pressure if present and manage underlying systemic conditions. The cornerstone of management is early recognition and urgent ophthalmologic referral.
Emergency Department Management
No therapy has proven definitive benefit in the ED setting. In consultation with ophthalmology, attempted therapies may include aspirin, anti-inflammatory agents, systemic corticosteroids, systemic anticoagulation, fibrinolytics (controversial), or laser chorioretinal anastomosis.
Definitive and Ophthalmologic Therapies
Ophthalmologists may use intravitreal corticosteroids such as triamcinolone or antivascular endothelial growth factor agents such as bevacizumab. Panretinal photocoagulation is often performed if neovascularization develops.
Disposition and Follow-Up
Admission depends on ophthalmologic assessment and need for intervention. Patients may be discharged if immediate ophthalmology follow-up is ensured. If ophthalmologic care is unavailable, initiate management of associated conditions and transfer to a facility with specialty services. Long-term follow-up is essential, particularly for ischemic CRVO, to detect neovascularization and secondary glaucoma. Patients require full medical evaluation for underlying vascular disease and comorbidity management.
Clinical Insights and Pitfalls
Elevated intraocular pressure from edema or neovascularization can worsen ischemia and lead to permanent vision loss if untreated. Bilateral CRVO or CRVO in young patients should prompt evaluation for hyperviscosity syndromes and systemic disease.
Overview
Central retinal vein occlusion (CRVO) is characterized by decreased visual acuity due to venous outflow obstruction of the retina. Vision loss is typically acute, unilateral, and painless. The condition results from impaired venous drainage leading to retinal hemorrhage, edema, and ischemia.
Pathophysiologic Types
Ischemic CRVO accounts for approximately 20–25% of cases and represents complete venous obstruction. Blocked venous return causes capillary backflow, extensive hemorrhage, macular edema, and retinal ischemia. Thrombosis is promoted by limited space at the lamina cribrosa, slow blood flow, vessel wall changes, adjacent arteriosclerotic arterial compression, and increased blood viscosity.
Nonischemic CRVO represents partial or incomplete occlusion and is generally milder with better visual prognosis.
Clinical Features
Patients present with acute, painless, unilateral loss of vision. In nonischemic CRVO, vision loss may be intermittent or incomplete. Visual acuity is often severely reduced, commonly worse than 20/200. An afferent pupillary defect may be present. Fundoscopic examination reveals dilated and tortuous retinal veins, widespread retinal hemorrhages involving all four quadrants in central involvement, optic disc edema, and cotton wool spots. Extensive hemorrhage produces the classic “blood and thunder” appearance.
Essential Assessment
Measure blood pressure. Perform visual acuity testing, visual field assessment, fundoscopy, and tonometry. Normal intraocular pressure ranges from 10–21 mm Hg.
Diagnostic Evaluation
Laboratory studies include CBC, PT/PTT, ESR, ANA, and serum protein electrophoresis to assess for systemic or hyperviscosity conditions. Fluorescein angiography, performed by ophthalmology, differentiates ischemic from nonischemic CRVO by identifying areas of capillary nonperfusion. Gonioscopy is used to evaluate for iris or angle neovascularization.
Differential Considerations
Amaurosis fugax or TIA, cavernous sinus thrombosis, diabetic or hypertensive retinopathy, hyperviscosity syndromes (sickle cell disease, polycythemia, leukemia, multiple myeloma), ocular ischemia syndrome, papilledema, retinal artery occlusion, retinal detachment, temporal arteritis, vitreous hemorrhage, severe anemia with thrombocytopenia, and functional vision loss.
Initial Management Principles
There are no prehospital eye-specific interventions. In the ED, address elevated intraocular pressure if present and manage underlying systemic conditions. The cornerstone of management is early recognition and urgent ophthalmologic referral.
Emergency Department Management
No therapy has proven definitive benefit in the ED setting. In consultation with ophthalmology, attempted therapies may include aspirin, anti-inflammatory agents, systemic corticosteroids, systemic anticoagulation, fibrinolytics (controversial), or laser chorioretinal anastomosis.
Definitive and Ophthalmologic Therapies
Ophthalmologists may use intravitreal corticosteroids such as triamcinolone or antivascular endothelial growth factor agents such as bevacizumab. Panretinal photocoagulation is often performed if neovascularization develops.
Disposition and Follow-Up
Admission depends on ophthalmologic assessment and need for intervention. Patients may be discharged if immediate ophthalmology follow-up is ensured. If ophthalmologic care is unavailable, initiate management of associated conditions and transfer to a facility with specialty services. Long-term follow-up is essential, particularly for ischemic CRVO, to detect neovascularization and secondary glaucoma. Patients require full medical evaluation for underlying vascular disease and comorbidity management.
Clinical Insights and Pitfalls
Elevated intraocular pressure from edema or neovascularization can worsen ischemia and lead to permanent vision loss if untreated. Bilateral CRVO or CRVO in young patients should prompt evaluation for hyperviscosity syndromes and systemic disease.
- Published on
Emergency and Acute Medicine - Cerebrovascular Accident (Stroke)
Overview
A cerebrovascular accident (CVA) results from interruption of blood flow to a specific brain region. Clinical deficits correspond to the vascular territory involved. Onset may be abrupt and complete or stepwise and fluctuating. Stroke accounts for ~1 in 18 deaths in the United States, with ~610,000 new cases annually.
Predisposing Factors
Hypertension, diabetes mellitus, smoking, coronary artery disease, cardiac dysrhythmias, peripheral vascular disease, oral contraceptive use, polycythemia vera, sickle cell disease, antithrombin III deficiency, protein C or S deficiency.
Pathologic Mechanisms
Ischemic stroke includes thrombotic, embolic, dissection-related, or hypoperfusion etiologies. Thrombotic stroke most often results from clot formation at an ulcerated atherosclerotic plaque or from sludging states (sickle cell disease, polycythemia vera, protein C deficiency). Embolic stroke arises from cardiac mural thrombi (atrial fibrillation, mitral stenosis, cardiomyopathy, CHF, MI), prosthetic or abnormal valves, carotid or aortic arch plaques, atrial myxoma, or ventricular aneurysm thrombi. Arterial dissection may involve carotid arteries or be associated with arteritis (giant cell, Takayasu) or fibromuscular dysplasia. Global ischemic stroke results from systemic hypotension due to sepsis, hemorrhage, or shock. Hemorrhagic stroke includes intracerebral and subarachnoid hemorrhage.
Pediatrics: Usually secondary to underlying disease (sickle cell disease, leukemia, infection, blood dyscrasia); younger children often present with seizures or altered mental status.
Clinical Features
History focuses on exact time of onset or last known normal, trauma or surgery, medications, confusion, headache, vertigo, and focal neurologic deficits.
General exam may show Cheyne–Stokes respirations, apnea, hypertension, dysrhythmias, or murmurs.
Anterior cerebral artery involvement causes contralateral leg-predominant weakness and sensory loss, apraxia, confusion, and impaired judgment.
Middle cerebral artery involvement causes contralateral face and arm weakness, hemisensory loss, homonymous hemianopsia, aphasia or dysarthria, and agnosia.
Posterior cerebral artery involvement causes cortical blindness, visual agnosia, memory impairment, altered mental status, third-nerve palsy, or hemiballismus.
Vertebrobasilar strokes cause vertigo, diplopia, nystagmus, visual field defects, and crossed cranial nerve and motor deficits; basilar artery occlusion may lead to quadriplegia, locked-in syndrome, or coma.
Watershed infarcts produce proximal limb weakness with sparing of face, hands, and feet.
Initial Evaluation Priorities
Perform a focused neurologic examination and calculate the NIH Stroke Scale when possible. Obtain emergent noncontrast head CT to differentiate ischemic from hemorrhagic stroke; early CT may be normal within 24–48 hours. Goals include CT completion within 25 minutes, interpretation within 45 minutes, and thrombolytic administration within 60 minutes if indicated. If CT is negative but subarachnoid hemorrhage is suspected, perform lumbar puncture. Obtain ECG, oxygen saturation, and rapid blood glucose.
Diagnostic Studies
Laboratory tests include CBC, electrolytes, renal and liver function, PT/PTT, urinalysis, and ESR when indicated. Additional studies may include cardiac enzymes, pregnancy test, toxicology screen, alcohol level, ABG, and blood cultures. Imaging may include MRI for early ischemia, chest radiograph, and carotid ultrasound. ECG evaluates for arrhythmia; lumbar puncture is required if CT is nondiagnostic and SAH remains suspected.
Key Differentials
Intracranial hemorrhage, hypoglycemia, seizure with Todd paralysis, conversion disorder, transient global amnesia, encephalitis or meningitis, peripheral neuropathy, intracranial abscess, migraine, air embolism, TIA, metabolic encephalopathy, neoplasm, vasculitis, multiple sclerosis, compressive myelopathy, vestibulitis, medication or toxin effects.
Prehospital Considerations
Patients may have impaired movement or communication. Field neurologic assessment should include level of consciousness, GCS, speech, facial symmetry, gait, and motor deficits. Fingerstick glucose is essential.
Stabilization Measures
Ensure airway protection; provide supplemental oxygen at 2–4 L/min. Intubation may be required for airway control or ICP management. For altered mental status, administer naloxone and thiamine and correct hypoglycemia.
Emergency Department Management
Treat severe hypertension only if SBP >220 mm Hg or DBP >120 mm Hg, or if required for comorbid conditions; initial target is <180 />10 mm Hg. Control seizures with benzodiazepines followed by fosphenytoin or phenytoin. Maintain euvolemia and normothermia.
Thrombolysis: For ischemic stroke only, administer IV alteplase within 4.5 hours of symptom onset if criteria are met. Avoid antiplatelet and anticoagulant therapy for 24 hours post-tPA.
Contraindications: Prior intracranial hemorrhage, recent stroke or head trauma (<3 months), major surgery (<14 days), uncontrolled hypertension, bleeding diathesis, recent mi, inr>1.7, platelets <100,000, intracranial neoplasm, seizure at onset, rapidly improving symptoms, pregnancy, recent internal bleeding, glucose <50 mg />L, age <18 years.< />pan>
3-4.5 hour exclusions: Age >80, oral anticoagulant use, NIHSS >25 or >1/3 MCA involvement, prior stroke plus diabetes.
Manage cerebral edema with head elevation, controlled ventilation (PaCO₂ 35–40 mm Hg), mannitol, and neurosurgical consultation when indicated. Selected patients may undergo intra-arterial thrombolysis or mechanical thrombectomy.
Medications
First line: Alteplase 0.9 mg/kg IV (max 90 mg), aspirin 81–325 mg PO/PR, labetalol IV bolus and infusion.
Second line: Clopidogrel, diazepam, enalapril, hydralazine, mannitol, nicardipine, nitroprusside, trimethaphan.
Pediatrics: Heparin or LMWH often used; pediatric stroke consultation available via 1-800-NOCLOTS.
Disposition
All acute strokes require hospital admission. ICU admission is indicated for depressed consciousness, hemodynamic instability, serious arrhythmias, elevated ICP, or tPA administration.
Discharge may be considered for completed strokes days to weeks old in patients who are functionally independent or have reliable support.
Follow-Up Care
Neurology consultation, primary care follow-up, and rehabilitation services including speech and occupational therapy.
Clinical Pearls
Document prehospital observations carefully. Accurate symptom onset time is critical for thrombolysis eligibility. Avoid rapid BP reduction to prevent cerebral hypoperfusion. Door-to-needle time goal is under 60 minutes.
Overview
A cerebrovascular accident (CVA) results from interruption of blood flow to a specific brain region. Clinical deficits correspond to the vascular territory involved. Onset may be abrupt and complete or stepwise and fluctuating. Stroke accounts for ~1 in 18 deaths in the United States, with ~610,000 new cases annually.
Predisposing Factors
Hypertension, diabetes mellitus, smoking, coronary artery disease, cardiac dysrhythmias, peripheral vascular disease, oral contraceptive use, polycythemia vera, sickle cell disease, antithrombin III deficiency, protein C or S deficiency.
Pathologic Mechanisms
Ischemic stroke includes thrombotic, embolic, dissection-related, or hypoperfusion etiologies. Thrombotic stroke most often results from clot formation at an ulcerated atherosclerotic plaque or from sludging states (sickle cell disease, polycythemia vera, protein C deficiency). Embolic stroke arises from cardiac mural thrombi (atrial fibrillation, mitral stenosis, cardiomyopathy, CHF, MI), prosthetic or abnormal valves, carotid or aortic arch plaques, atrial myxoma, or ventricular aneurysm thrombi. Arterial dissection may involve carotid arteries or be associated with arteritis (giant cell, Takayasu) or fibromuscular dysplasia. Global ischemic stroke results from systemic hypotension due to sepsis, hemorrhage, or shock. Hemorrhagic stroke includes intracerebral and subarachnoid hemorrhage.
Pediatrics: Usually secondary to underlying disease (sickle cell disease, leukemia, infection, blood dyscrasia); younger children often present with seizures or altered mental status.
Clinical Features
History focuses on exact time of onset or last known normal, trauma or surgery, medications, confusion, headache, vertigo, and focal neurologic deficits.
General exam may show Cheyne–Stokes respirations, apnea, hypertension, dysrhythmias, or murmurs.
Anterior cerebral artery involvement causes contralateral leg-predominant weakness and sensory loss, apraxia, confusion, and impaired judgment.
Middle cerebral artery involvement causes contralateral face and arm weakness, hemisensory loss, homonymous hemianopsia, aphasia or dysarthria, and agnosia.
Posterior cerebral artery involvement causes cortical blindness, visual agnosia, memory impairment, altered mental status, third-nerve palsy, or hemiballismus.
Vertebrobasilar strokes cause vertigo, diplopia, nystagmus, visual field defects, and crossed cranial nerve and motor deficits; basilar artery occlusion may lead to quadriplegia, locked-in syndrome, or coma.
Watershed infarcts produce proximal limb weakness with sparing of face, hands, and feet.
Initial Evaluation Priorities
Perform a focused neurologic examination and calculate the NIH Stroke Scale when possible. Obtain emergent noncontrast head CT to differentiate ischemic from hemorrhagic stroke; early CT may be normal within 24–48 hours. Goals include CT completion within 25 minutes, interpretation within 45 minutes, and thrombolytic administration within 60 minutes if indicated. If CT is negative but subarachnoid hemorrhage is suspected, perform lumbar puncture. Obtain ECG, oxygen saturation, and rapid blood glucose.
Diagnostic Studies
Laboratory tests include CBC, electrolytes, renal and liver function, PT/PTT, urinalysis, and ESR when indicated. Additional studies may include cardiac enzymes, pregnancy test, toxicology screen, alcohol level, ABG, and blood cultures. Imaging may include MRI for early ischemia, chest radiograph, and carotid ultrasound. ECG evaluates for arrhythmia; lumbar puncture is required if CT is nondiagnostic and SAH remains suspected.
Key Differentials
Intracranial hemorrhage, hypoglycemia, seizure with Todd paralysis, conversion disorder, transient global amnesia, encephalitis or meningitis, peripheral neuropathy, intracranial abscess, migraine, air embolism, TIA, metabolic encephalopathy, neoplasm, vasculitis, multiple sclerosis, compressive myelopathy, vestibulitis, medication or toxin effects.
Prehospital Considerations
Patients may have impaired movement or communication. Field neurologic assessment should include level of consciousness, GCS, speech, facial symmetry, gait, and motor deficits. Fingerstick glucose is essential.
Stabilization Measures
Ensure airway protection; provide supplemental oxygen at 2–4 L/min. Intubation may be required for airway control or ICP management. For altered mental status, administer naloxone and thiamine and correct hypoglycemia.
Emergency Department Management
Treat severe hypertension only if SBP >220 mm Hg or DBP >120 mm Hg, or if required for comorbid conditions; initial target is <180 />10 mm Hg. Control seizures with benzodiazepines followed by fosphenytoin or phenytoin. Maintain euvolemia and normothermia.
Thrombolysis: For ischemic stroke only, administer IV alteplase within 4.5 hours of symptom onset if criteria are met. Avoid antiplatelet and anticoagulant therapy for 24 hours post-tPA.
Contraindications: Prior intracranial hemorrhage, recent stroke or head trauma (<3 months), major surgery (<14 days), uncontrolled hypertension, bleeding diathesis, recent mi, inr>1.7, platelets <100,000, intracranial neoplasm, seizure at onset, rapidly improving symptoms, pregnancy, recent internal bleeding, glucose <50 mg />L, age <18 years.< />pan>
3-4.5 hour exclusions: Age >80, oral anticoagulant use, NIHSS >25 or >1/3 MCA involvement, prior stroke plus diabetes.
Manage cerebral edema with head elevation, controlled ventilation (PaCO₂ 35–40 mm Hg), mannitol, and neurosurgical consultation when indicated. Selected patients may undergo intra-arterial thrombolysis or mechanical thrombectomy.
Medications
First line: Alteplase 0.9 mg/kg IV (max 90 mg), aspirin 81–325 mg PO/PR, labetalol IV bolus and infusion.
Second line: Clopidogrel, diazepam, enalapril, hydralazine, mannitol, nicardipine, nitroprusside, trimethaphan.
Pediatrics: Heparin or LMWH often used; pediatric stroke consultation available via 1-800-NOCLOTS.
Disposition
All acute strokes require hospital admission. ICU admission is indicated for depressed consciousness, hemodynamic instability, serious arrhythmias, elevated ICP, or tPA administration.
Discharge may be considered for completed strokes days to weeks old in patients who are functionally independent or have reliable support.
Follow-Up Care
Neurology consultation, primary care follow-up, and rehabilitation services including speech and occupational therapy.
Clinical Pearls
Document prehospital observations carefully. Accurate symptom onset time is critical for thrombolysis eligibility. Avoid rapid BP reduction to prevent cerebral hypoperfusion. Door-to-needle time goal is under 60 minutes.
- Published on
Emergency and Acute Medicine – Cardiac Pacemakers
Core Concept
A cardiac pacemaker is an electronic device that delivers electrical impulses to stimulate myocardial contraction and maintain an adequate heart rate and cardiac output when intrinsic conduction is inadequate.
Pacing Modalities
Transcutaneous pacing uses external pads placed in anterior–lateral or anterior–posterior positions. Current is increased until electrical and mechanical capture is achieved. This is a temporary emergency measure until definitive therapy is available.
Temporary transvenous pacing involves insertion of a pacing wire via central venous access into the right atrium or ventricle, connected to an external generator. It is typically used as a bridge to permanent pacing or until pacing is no longer required.
Permanent implanted pacemakers consist of a lithium-powered battery (lifespan approximately 7–10 years), a programmable generator, and one or more leads positioned in the right atrium and/or ventricle to sense intrinsic activity and pace as needed.
A pacemaker magnet placed over the generator converts the device to asynchronous pacing. This is useful when pacer spikes are absent on ECG; a reduced magnet rate (≈10% decrease) suggests battery depletion.
Key Terminology
Fixed-rate pacing fires at a preset rate regardless of intrinsic rhythm and is now rarely used.
Demand pacing senses native cardiac activity and delivers impulses only when intrinsic rates fall below a programmed threshold.
Sensing refers to the device’s ability to detect intrinsic cardiac depolarization.
Pacemakers are described using a standardized code; in emergency care, the first three letters are most relevant: the chamber sensed, the chamber paced, and the response to sensing. Common configurations include VVI (single-chamber ventricular pacing) and DDD (dual-chamber pacing).
Common Causes of Pacemaker Complications
Infection of pacemaker components is most often due to Staphylococcus epidermidis or Staphylococcus aureus and may be associated with endocarditis; transesophageal echocardiography is preferred for diagnosis.
Venous thrombosis related to pacing leads is common but usually asymptomatic; pulmonary embolism is rare.
Failure to pace may result from lead fracture or disconnection, oversensing of muscle activity or electrical interference, or gradual battery depletion.
Failure to capture is commonly due to lead dislodgment, including Twiddler’s syndrome, or elevated myocardial pacing thresholds caused by hyperkalemia or ischemia.
Pacemaker-mediated tachycardia occurs in dual-chamber devices via re-entry involving the generator and intrinsic conduction system, typically limited to about 140 bpm.
Runaway pacemaker is rare and characterized by extremely rapid pacing (>200 bpm) due to component failure or battery depletion, often causing hemodynamic instability.
Clinical Presentation
Pacemaker failure may manifest as bradycardia, syncope, hypotension progressing to shock, fatigue, dyspnea from heart failure, ischemic chest pain, or altered mental status.
Pacemaker-induced tachycardia presents with dyspnea, chest pain, lightheadedness, or syncope.
Pacemaker syndrome, usually seen with ventricular-only pacing, results from atrioventricular dyssynchrony and causes palpitations, weakness, exercise intolerance, dyspnea, or syncope.
Focused History and Examination
Key history includes date of implantation, device type, and adherence to routine follow-up and battery checks. Examination should include cardiovascular and pulmonary assessment and inspection of the generator site for signs of infection.
Essential Emergency Evaluation
A 12-lead ECG is critical to identify pacing spikes, capture, sensing abnormalities, or dysrhythmias.
Metabolic evaluation should assess for reversible causes of elevated pacing thresholds.
ECG evaluation with a pacemaker magnet helps assess device function: normal magnet rate suggests intact function, a rate slowed by more than 10% indicates battery depletion, and absence of spikes suggests significant malfunction.
Diagnostic Studies
Laboratory testing includes serum potassium, arterial blood gas, and serum levels of antiarrhythmic drugs when relevant.
Chest radiography evaluates lead integrity and position, identifying fractures, dislodgment, or perforation.
Prehospital Considerations
Obtain and preserve rhythm strips for later analysis.
Initial Stabilization
Administer supplemental oxygen, secure the airway if needed, establish IV access, and treat bradycardia per ACLS protocols. Avoid placing defibrillation pads directly over the pacemaker generator. Initiate transcutaneous pacing in unstable patients.
Definitive Emergency Management
For pacemaker failure with instability, initiate transcutaneous pacing and arrange for temporary transvenous pacing via central venous access, preferably the right internal jugular vein. Confirm capture electrically and mechanically, determine capture threshold, and set output at two to three times this threshold.
Correct reversible causes such as hyperkalemia.
Pacemaker-mediated or runaway tachycardia may require AV nodal blockade, device reprogramming, or, in extreme cases, surgical disconnection of the lead.
Medications
Adenosine 6 mg IV bolus may be used in select tachyarrhythmias, with cardiology guidance.
Disposition Planning
Admission is required for permanent pacemaker malfunction or suspected device-related infection.
Patients may be discharged only if asymptomatic and after formal device interrogation by cardiology.
Follow-Up Strategy
All patients require referral to cardiology or a specialized pacemaker clinic for definitive evaluation and management.
Clinical Pearls and Pitfalls
Always consider pacemaker malfunction in patients presenting with unexplained bradycardia, syncope, or decompensated heart failure. Early use of a pacemaker magnet is a simple and valuable diagnostic tool in the emergency setting.
Core Concept
A cardiac pacemaker is an electronic device that delivers electrical impulses to stimulate myocardial contraction and maintain an adequate heart rate and cardiac output when intrinsic conduction is inadequate.
Pacing Modalities
Transcutaneous pacing uses external pads placed in anterior–lateral or anterior–posterior positions. Current is increased until electrical and mechanical capture is achieved. This is a temporary emergency measure until definitive therapy is available.
Temporary transvenous pacing involves insertion of a pacing wire via central venous access into the right atrium or ventricle, connected to an external generator. It is typically used as a bridge to permanent pacing or until pacing is no longer required.
Permanent implanted pacemakers consist of a lithium-powered battery (lifespan approximately 7–10 years), a programmable generator, and one or more leads positioned in the right atrium and/or ventricle to sense intrinsic activity and pace as needed.
A pacemaker magnet placed over the generator converts the device to asynchronous pacing. This is useful when pacer spikes are absent on ECG; a reduced magnet rate (≈10% decrease) suggests battery depletion.
Key Terminology
Fixed-rate pacing fires at a preset rate regardless of intrinsic rhythm and is now rarely used.
Demand pacing senses native cardiac activity and delivers impulses only when intrinsic rates fall below a programmed threshold.
Sensing refers to the device’s ability to detect intrinsic cardiac depolarization.
Pacemakers are described using a standardized code; in emergency care, the first three letters are most relevant: the chamber sensed, the chamber paced, and the response to sensing. Common configurations include VVI (single-chamber ventricular pacing) and DDD (dual-chamber pacing).
Common Causes of Pacemaker Complications
Infection of pacemaker components is most often due to Staphylococcus epidermidis or Staphylococcus aureus and may be associated with endocarditis; transesophageal echocardiography is preferred for diagnosis.
Venous thrombosis related to pacing leads is common but usually asymptomatic; pulmonary embolism is rare.
Failure to pace may result from lead fracture or disconnection, oversensing of muscle activity or electrical interference, or gradual battery depletion.
Failure to capture is commonly due to lead dislodgment, including Twiddler’s syndrome, or elevated myocardial pacing thresholds caused by hyperkalemia or ischemia.
Pacemaker-mediated tachycardia occurs in dual-chamber devices via re-entry involving the generator and intrinsic conduction system, typically limited to about 140 bpm.
Runaway pacemaker is rare and characterized by extremely rapid pacing (>200 bpm) due to component failure or battery depletion, often causing hemodynamic instability.
Clinical Presentation
Pacemaker failure may manifest as bradycardia, syncope, hypotension progressing to shock, fatigue, dyspnea from heart failure, ischemic chest pain, or altered mental status.
Pacemaker-induced tachycardia presents with dyspnea, chest pain, lightheadedness, or syncope.
Pacemaker syndrome, usually seen with ventricular-only pacing, results from atrioventricular dyssynchrony and causes palpitations, weakness, exercise intolerance, dyspnea, or syncope.
Focused History and Examination
Key history includes date of implantation, device type, and adherence to routine follow-up and battery checks. Examination should include cardiovascular and pulmonary assessment and inspection of the generator site for signs of infection.
Essential Emergency Evaluation
A 12-lead ECG is critical to identify pacing spikes, capture, sensing abnormalities, or dysrhythmias.
Metabolic evaluation should assess for reversible causes of elevated pacing thresholds.
ECG evaluation with a pacemaker magnet helps assess device function: normal magnet rate suggests intact function, a rate slowed by more than 10% indicates battery depletion, and absence of spikes suggests significant malfunction.
Diagnostic Studies
Laboratory testing includes serum potassium, arterial blood gas, and serum levels of antiarrhythmic drugs when relevant.
Chest radiography evaluates lead integrity and position, identifying fractures, dislodgment, or perforation.
Prehospital Considerations
Obtain and preserve rhythm strips for later analysis.
Initial Stabilization
Administer supplemental oxygen, secure the airway if needed, establish IV access, and treat bradycardia per ACLS protocols. Avoid placing defibrillation pads directly over the pacemaker generator. Initiate transcutaneous pacing in unstable patients.
Definitive Emergency Management
For pacemaker failure with instability, initiate transcutaneous pacing and arrange for temporary transvenous pacing via central venous access, preferably the right internal jugular vein. Confirm capture electrically and mechanically, determine capture threshold, and set output at two to three times this threshold.
Correct reversible causes such as hyperkalemia.
Pacemaker-mediated or runaway tachycardia may require AV nodal blockade, device reprogramming, or, in extreme cases, surgical disconnection of the lead.
Medications
Adenosine 6 mg IV bolus may be used in select tachyarrhythmias, with cardiology guidance.
Disposition Planning
Admission is required for permanent pacemaker malfunction or suspected device-related infection.
Patients may be discharged only if asymptomatic and after formal device interrogation by cardiology.
Follow-Up Strategy
All patients require referral to cardiology or a specialized pacemaker clinic for definitive evaluation and management.
Clinical Pearls and Pitfalls
Always consider pacemaker malfunction in patients presenting with unexplained bradycardia, syncope, or decompensated heart failure. Early use of a pacemaker magnet is a simple and valuable diagnostic tool in the emergency setting.
- Published on
Emergency and Acute Medicine – Cardiac Testing
Overview
Cardiac testing is essential in emergency patients with concern for acute coronary syndrome (ACS) or heart failure (HF). These entities exist on a continuum, where unstable angina may progress to myocardial infarction and subsequently to heart failure. Missed ACS remains a major source of emergency department malpractice, with a small but significant percentage of ACS patients discharged inappropriately. History, physical examination, and ECG are the foundation of evaluation but fail to detect a minority of myocardial infarctions, necessitating adjunctive testing such as biomarkers and imaging.
Underlying Causes
ACS most commonly results from atherosclerotic coronary artery disease or coronary vasospasm. In pregnancy, spontaneous coronary artery dissection should be considered when ischemic ECG changes accompany chest pain.
Clinical Presentation
Anginal discomfort is typically provoked by exertion or emotional stress and relieved by rest. Chest pain described as sharp, stabbing, pleuritic, or reproducible by palpation is less suggestive of ACS, though ischemia can still be present in a minority of these cases. Symptom relief with nitroglycerin or gastrointestinal treatments does not reliably distinguish cardiac from noncardiac causes. Anginal episodes often last more than 5 minutes but less than 20 minutes; symptoms persisting beyond 20 minutes raise concern for unstable angina or infarction. Physical examination is frequently normal.
Core Emergency Evaluation
A 12-lead ECG should be obtained within 10 minutes of arrival for patients with chest pain. A single ECG may miss up to half of acute myocardial infarctions, as changes can evolve over time. Hyperacute T waves may represent the earliest ischemic sign. Continuous ECG monitoring or repeat ECGs within 15–60 minutes improves detection. ST-segment depression of 1 mm suggests ischemia, while ST elevation greater than 1–2 mm in contiguous leads defines STEMI. New left bundle branch block complicates diagnosis; concordant ST changes using Sgarbossa criteria increase suspicion. Additional ECG leads may identify infarctions not seen on standard views, including right ventricular and posterior wall involvement.
Laboratory Assessment
Cardiac biomarkers are indicated when ACS is suspected. Troponin I and T rise within 2–3 hours, peak by 8–12 hours, and remain elevated for days. A single negative troponin has limited sensitivity unless drawn 8–12 hours after symptom onset. Mild elevations may occur in nonischemic conditions such as renal failure, sepsis, pulmonary embolism, or heart failure. CK-MB is less sensitive and generally adds little unless renal failure or recent infarction limits troponin interpretation. BNP assists in diagnosing heart failure, with levels above 100 pg/mL supporting the diagnosis.
Imaging Modalities
Chest radiography is often normal but may reveal cardiomegaly, pulmonary edema, pneumonia, or mediastinal widening. Rest echocardiography can identify wall motion abnormalities and pump failure, providing moderate sensitivity for ACS and higher sensitivity for myocardial infarction. Myocardial perfusion imaging using technetium-99m sestamibi detects regions of reduced perfusion and is reserved for intermediate- to high-risk patients. CT coronary angiography offers a high negative predictive value but may increase downstream testing without reducing cost. Exercise stress testing provides diagnostic and prognostic information, with enhanced accuracy when combined with echocardiography or nuclear imaging. Cardiac catheterization remains the gold standard for coronary assessment but does not exclude vasospasm-related events.
Prehospital and Initial ED Management
Prehospital ECG monitoring improves early detection of ACS. In the emergency department, continuous cardiac monitoring and pulse oximetry are standard. Further management depends on risk stratification and test results.
Diagnostic Strategy in the ED
Patients with concerning history should undergo ECG and initial troponin testing. Abnormal findings warrant admission and cardiology consultation. Persistent symptoms or evolving ECG changes necessitate repeat testing or advanced imaging. Low- to moderate-risk patients may undergo stress testing, either during observation or as an outpatient within 72 hours if reliable follow-up exists. Abnormal ancillary testing requires admission or specialty consultation.
Disposition Planning
Admission is indicated for patients with abnormal ECGs, positive biomarkers, concerning imaging, or unavailable observation resources. Observation units may be used for serial testing when diagnosis is uncertain. Discharge is appropriate for patients with noncardiac histories, normal ECGs, and negative cardiac testing.
Follow-Up Considerations
Abnormal stress tests require close cardiology follow-up. Patients discharged with undifferentiated chest pain should have timely outpatient evaluation if inpatient testing is deferred.
Clinical Insights and Cautions
A normal ECG or troponin does not exclude coronary artery disease. Serial ECGs and additional leads increase diagnostic sensitivity. Most emergency patients with undifferentiated chest pain require some form of additional cardiac testing to safely exclude ACS.
Overview
Cardiac testing is essential in emergency patients with concern for acute coronary syndrome (ACS) or heart failure (HF). These entities exist on a continuum, where unstable angina may progress to myocardial infarction and subsequently to heart failure. Missed ACS remains a major source of emergency department malpractice, with a small but significant percentage of ACS patients discharged inappropriately. History, physical examination, and ECG are the foundation of evaluation but fail to detect a minority of myocardial infarctions, necessitating adjunctive testing such as biomarkers and imaging.
Underlying Causes
ACS most commonly results from atherosclerotic coronary artery disease or coronary vasospasm. In pregnancy, spontaneous coronary artery dissection should be considered when ischemic ECG changes accompany chest pain.
Clinical Presentation
Anginal discomfort is typically provoked by exertion or emotional stress and relieved by rest. Chest pain described as sharp, stabbing, pleuritic, or reproducible by palpation is less suggestive of ACS, though ischemia can still be present in a minority of these cases. Symptom relief with nitroglycerin or gastrointestinal treatments does not reliably distinguish cardiac from noncardiac causes. Anginal episodes often last more than 5 minutes but less than 20 minutes; symptoms persisting beyond 20 minutes raise concern for unstable angina or infarction. Physical examination is frequently normal.
Core Emergency Evaluation
A 12-lead ECG should be obtained within 10 minutes of arrival for patients with chest pain. A single ECG may miss up to half of acute myocardial infarctions, as changes can evolve over time. Hyperacute T waves may represent the earliest ischemic sign. Continuous ECG monitoring or repeat ECGs within 15–60 minutes improves detection. ST-segment depression of 1 mm suggests ischemia, while ST elevation greater than 1–2 mm in contiguous leads defines STEMI. New left bundle branch block complicates diagnosis; concordant ST changes using Sgarbossa criteria increase suspicion. Additional ECG leads may identify infarctions not seen on standard views, including right ventricular and posterior wall involvement.
Laboratory Assessment
Cardiac biomarkers are indicated when ACS is suspected. Troponin I and T rise within 2–3 hours, peak by 8–12 hours, and remain elevated for days. A single negative troponin has limited sensitivity unless drawn 8–12 hours after symptom onset. Mild elevations may occur in nonischemic conditions such as renal failure, sepsis, pulmonary embolism, or heart failure. CK-MB is less sensitive and generally adds little unless renal failure or recent infarction limits troponin interpretation. BNP assists in diagnosing heart failure, with levels above 100 pg/mL supporting the diagnosis.
Imaging Modalities
Chest radiography is often normal but may reveal cardiomegaly, pulmonary edema, pneumonia, or mediastinal widening. Rest echocardiography can identify wall motion abnormalities and pump failure, providing moderate sensitivity for ACS and higher sensitivity for myocardial infarction. Myocardial perfusion imaging using technetium-99m sestamibi detects regions of reduced perfusion and is reserved for intermediate- to high-risk patients. CT coronary angiography offers a high negative predictive value but may increase downstream testing without reducing cost. Exercise stress testing provides diagnostic and prognostic information, with enhanced accuracy when combined with echocardiography or nuclear imaging. Cardiac catheterization remains the gold standard for coronary assessment but does not exclude vasospasm-related events.
Prehospital and Initial ED Management
Prehospital ECG monitoring improves early detection of ACS. In the emergency department, continuous cardiac monitoring and pulse oximetry are standard. Further management depends on risk stratification and test results.
Diagnostic Strategy in the ED
Patients with concerning history should undergo ECG and initial troponin testing. Abnormal findings warrant admission and cardiology consultation. Persistent symptoms or evolving ECG changes necessitate repeat testing or advanced imaging. Low- to moderate-risk patients may undergo stress testing, either during observation or as an outpatient within 72 hours if reliable follow-up exists. Abnormal ancillary testing requires admission or specialty consultation.
Disposition Planning
Admission is indicated for patients with abnormal ECGs, positive biomarkers, concerning imaging, or unavailable observation resources. Observation units may be used for serial testing when diagnosis is uncertain. Discharge is appropriate for patients with noncardiac histories, normal ECGs, and negative cardiac testing.
Follow-Up Considerations
Abnormal stress tests require close cardiology follow-up. Patients discharged with undifferentiated chest pain should have timely outpatient evaluation if inpatient testing is deferred.
Clinical Insights and Cautions
A normal ECG or troponin does not exclude coronary artery disease. Serial ECGs and additional leads increase diagnostic sensitivity. Most emergency patients with undifferentiated chest pain require some form of additional cardiac testing to safely exclude ACS.
- Published on
Emergency and Acute Medicine – Cardiac Transplantation Complications
Overview
Heart transplant recipients represent a high-risk emergency population because of denervated graft physiology and chronic immunosuppression. They are vulnerable to ischemia, heart failure, infection, and medication toxicity. Approximately 1,900–2,300 cardiac transplants are performed annually in the United States, with survival rates of 85–90% at 1 year and about 75% at 5 years. Most patients receive triple-drug immunosuppressive regimens, commonly including corticosteroids. The highest complication rate occurs within the first 6 weeks post-transplant, though late complications are common.
Special Populations
Older transplant recipients have increased susceptibility to severe infection and acute rejection due to age-related immune changes. Pregnancy after cardiac transplantation is increasingly reported and usually results in live births, though hypertension, preeclampsia, and rejection are common. Physiologic changes of pregnancy do not significantly increase heart failure risk, but vigilance for infection and rejection is essential.
Mechanisms of Complications
Rejection may be hyperacute, acute, or chronic. Hyperacute rejection occurs within minutes due to ABO or major incompatibility and is immediately graft-fatal. Acute rejection, characterized by lymphocytic infiltration and myocyte injury, is most common in the first 6 weeks but can occur at any time. Chronic rejection manifests as fibrosis and graft vascular disease and has no effective therapy. Cardiac allograft vasculopathy represents immune-mediated accelerated coronary disease and is the leading cause of late mortality beyond the first year.
Infectious complications dominate early outcomes. During the first month, bacterial infections such as pneumonia, mediastinitis, wound infections, and UTIs are common. Within the first year, opportunistic infections including CMV, HSV, Legionella, fungi, and Pneumocystis become prominent. Medication toxicities are frequent, particularly nephrotoxicity, neurotoxicity, metabolic derangements, and bone marrow suppression from immunosuppressants. Long-term immunosuppression markedly increases malignancy risk, especially skin cancers, lymphomas, Kaposi sarcoma, and solid tumors.
Clinical Manifestations
Acute rejection presents with nonspecific symptoms due to cardiac denervation, including fatigue, dyspnea, low-grade fever, nausea, and vomiting. Heart failure may manifest as tachypnea, rales, hypoxia, S3 gallop, murmurs, and edema. Allograft vasculopathy often presents insidiously with fatigue, cough, or dyspnea; acute presentations include heart failure, infarction, or sudden death, often without angina. Infection may present with fever, skin lesions, or organ-specific symptoms. CMV infection ranges from mild flu-like illness to pneumonitis, hepatitis, gastroenteritis, and severe leukopenia with high mortality. Pediatric patients have higher risk of post-transplant lymphoproliferative disease and pneumonia.
Essential Emergency Assessment
Evaluation focuses on identifying rejection, graft dysfunction, ischemia, and infection. Initial studies include ECG, cardiac enzymes, chest radiograph, and echocardiography. Suspected rejection requires urgent consultation with the transplant team and often endomyocardial biopsy. In children, standard fever evaluation with chest radiograph and ECG is required, and lumbar puncture should be considered if the patient is on steroids.
Diagnostic Findings
Laboratory abnormalities may include renal dysfunction, electrolyte disturbances, metabolic acidosis, and hyperkalemia related to calcineurin inhibitors. Relative eosinophilia may favor rejection over infection. BNP is often chronically elevated. CMV testing and immunosuppressant trough levels are frequently necessary. ECG typically shows sinus tachycardia (90–110 bpm) in denervated hearts; voltage reduction may be seen. Chest radiography may reveal cardiomegaly, pulmonary edema, or effusions. Echocardiography may show diastolic dysfunction, biventricular dilation, valvular regurgitation, or reduced filling parameters.
Key Differentials
Rejection, infection, ischemia, CMV disease, malignancy, and medication toxicity should always be considered.
Prehospital Considerations
Adenosine should be avoided due to prolonged and unpredictable effects in denervated hearts.
Initial Stabilization
Management follows airway, breathing, and circulation priorities with oxygen, IV access, monitoring, and ventilatory or hemodynamic support as needed. Bradycardia does not respond to atropine; isoproterenol is preferred. ACLS protocols apply, with awareness of altered pharmacologic responses.
Emergency Department Management
Hemodynamically significant rejection requires high-dose IV corticosteroids and possible anti–T-cell antibody therapy in coordination with the transplant team. Ischemia or vasculopathy is treated with antiplatelet therapy, anticoagulation, and possible revascularization, though retransplantation may ultimately be required. Suspected CMV infection warrants empiric IV ganciclovir. HSV infections are treated with acyclovir. Fever without source mandates early infectious disease or transplant consultation. Headache or neurologic symptoms require low threshold for neuroimaging and lumbar puncture. Stress-dose steroids may be required during severe illness or trauma, and NSAIDs should be minimized due to nephrotoxicity risk.
Disposition Planning
Admission is indicated for hemodynamically significant rejection, ischemia, new dysrhythmias, heart failure, hypoxia, syncope, poorly controlled hypertension, suspected CMV infection, inability to tolerate oral medications, or fever in immunosuppressed patients. Discharge for mild rejection or select pediatric fever cases should occur only after direct consultation with the transplant team.
Clinical Insights
Symptoms of rejection and infection overlap and are often subtle. Denervated hearts mask classic ischemic pain. Bradycardia will not respond to atropine. Early consultation with the transplant center is essential for optimal outcomes.
Overview
Heart transplant recipients represent a high-risk emergency population because of denervated graft physiology and chronic immunosuppression. They are vulnerable to ischemia, heart failure, infection, and medication toxicity. Approximately 1,900–2,300 cardiac transplants are performed annually in the United States, with survival rates of 85–90% at 1 year and about 75% at 5 years. Most patients receive triple-drug immunosuppressive regimens, commonly including corticosteroids. The highest complication rate occurs within the first 6 weeks post-transplant, though late complications are common.
Special Populations
Older transplant recipients have increased susceptibility to severe infection and acute rejection due to age-related immune changes. Pregnancy after cardiac transplantation is increasingly reported and usually results in live births, though hypertension, preeclampsia, and rejection are common. Physiologic changes of pregnancy do not significantly increase heart failure risk, but vigilance for infection and rejection is essential.
Mechanisms of Complications
Rejection may be hyperacute, acute, or chronic. Hyperacute rejection occurs within minutes due to ABO or major incompatibility and is immediately graft-fatal. Acute rejection, characterized by lymphocytic infiltration and myocyte injury, is most common in the first 6 weeks but can occur at any time. Chronic rejection manifests as fibrosis and graft vascular disease and has no effective therapy. Cardiac allograft vasculopathy represents immune-mediated accelerated coronary disease and is the leading cause of late mortality beyond the first year.
Infectious complications dominate early outcomes. During the first month, bacterial infections such as pneumonia, mediastinitis, wound infections, and UTIs are common. Within the first year, opportunistic infections including CMV, HSV, Legionella, fungi, and Pneumocystis become prominent. Medication toxicities are frequent, particularly nephrotoxicity, neurotoxicity, metabolic derangements, and bone marrow suppression from immunosuppressants. Long-term immunosuppression markedly increases malignancy risk, especially skin cancers, lymphomas, Kaposi sarcoma, and solid tumors.
Clinical Manifestations
Acute rejection presents with nonspecific symptoms due to cardiac denervation, including fatigue, dyspnea, low-grade fever, nausea, and vomiting. Heart failure may manifest as tachypnea, rales, hypoxia, S3 gallop, murmurs, and edema. Allograft vasculopathy often presents insidiously with fatigue, cough, or dyspnea; acute presentations include heart failure, infarction, or sudden death, often without angina. Infection may present with fever, skin lesions, or organ-specific symptoms. CMV infection ranges from mild flu-like illness to pneumonitis, hepatitis, gastroenteritis, and severe leukopenia with high mortality. Pediatric patients have higher risk of post-transplant lymphoproliferative disease and pneumonia.
Essential Emergency Assessment
Evaluation focuses on identifying rejection, graft dysfunction, ischemia, and infection. Initial studies include ECG, cardiac enzymes, chest radiograph, and echocardiography. Suspected rejection requires urgent consultation with the transplant team and often endomyocardial biopsy. In children, standard fever evaluation with chest radiograph and ECG is required, and lumbar puncture should be considered if the patient is on steroids.
Diagnostic Findings
Laboratory abnormalities may include renal dysfunction, electrolyte disturbances, metabolic acidosis, and hyperkalemia related to calcineurin inhibitors. Relative eosinophilia may favor rejection over infection. BNP is often chronically elevated. CMV testing and immunosuppressant trough levels are frequently necessary. ECG typically shows sinus tachycardia (90–110 bpm) in denervated hearts; voltage reduction may be seen. Chest radiography may reveal cardiomegaly, pulmonary edema, or effusions. Echocardiography may show diastolic dysfunction, biventricular dilation, valvular regurgitation, or reduced filling parameters.
Key Differentials
Rejection, infection, ischemia, CMV disease, malignancy, and medication toxicity should always be considered.
Prehospital Considerations
Adenosine should be avoided due to prolonged and unpredictable effects in denervated hearts.
Initial Stabilization
Management follows airway, breathing, and circulation priorities with oxygen, IV access, monitoring, and ventilatory or hemodynamic support as needed. Bradycardia does not respond to atropine; isoproterenol is preferred. ACLS protocols apply, with awareness of altered pharmacologic responses.
Emergency Department Management
Hemodynamically significant rejection requires high-dose IV corticosteroids and possible anti–T-cell antibody therapy in coordination with the transplant team. Ischemia or vasculopathy is treated with antiplatelet therapy, anticoagulation, and possible revascularization, though retransplantation may ultimately be required. Suspected CMV infection warrants empiric IV ganciclovir. HSV infections are treated with acyclovir. Fever without source mandates early infectious disease or transplant consultation. Headache or neurologic symptoms require low threshold for neuroimaging and lumbar puncture. Stress-dose steroids may be required during severe illness or trauma, and NSAIDs should be minimized due to nephrotoxicity risk.
Disposition Planning
Admission is indicated for hemodynamically significant rejection, ischemia, new dysrhythmias, heart failure, hypoxia, syncope, poorly controlled hypertension, suspected CMV infection, inability to tolerate oral medications, or fever in immunosuppressed patients. Discharge for mild rejection or select pediatric fever cases should occur only after direct consultation with the transplant team.
Clinical Insights
Symptoms of rejection and infection overlap and are often subtle. Denervated hearts mask classic ischemic pain. Bradycardia will not respond to atropine. Early consultation with the transplant center is essential for optimal outcomes.
- Published on
Emergency and Acute Medicine – Hypertrophic Cardiomyopathy
Core Overview
Hypertrophic cardiomyopathy (HCM) is a genetic disorder of the cardiac sarcomere caused by numerous mutations, resulting in a hypertrophied, nondilated left ventricle (and rarely right ventricle) without another cause such as hypertension or aortic stenosis. Phenotypic expression is highly variable. Two major forms exist: nonobstructive HCM, accounting for approximately 75% of patients with an estimated annual mortality of ~1%, and obstructive hypertrophic cardiomyopathy (HOCM), accounting for ~25% with more severe disease and an estimated annual mortality of ~2%.
HCM can present at any age, from neonates to the elderly, but most cases manifest during childhood or adolescence, often coinciding with the pubertal growth spurt. Disease diagnosed at younger ages is typically more severe. A small subset progresses to reduced left ventricular systolic function later in life. Adult-onset presentations are not uncommon and are frequently misdiagnosed as asthma, COPD, deconditioning, or sleep apnea. Lethal ventricular arrhythmias are more common in younger patients, while supraventricular arrhythmias increase with age. Atrial fibrillation is common and often poorly tolerated. HCM is the most common cause of atraumatic sudden death in young athletes under 35 years of age. Prevalence is approximately 1 in 500 adults based on echocardiographic screening.
Structural and Pathophysiologic Features
Pathology is characterized by marked and irregular ventricular wall thickening with myofibrillar disarray and fibrin deposition, predominantly affecting the high-pressure left ventricle. Septal hypertrophy is usually more pronounced than free wall thickening. In obstructive disease, hypertrophy may regress if outflow obstruction is relieved. Some phenotypes demonstrate progressive wall thinning with age, typically following marked hypertrophy earlier in life. Diastolic stiffness leads to atrial dilation. Microvascular dysfunction occurs due to impaired vasodilation, intimal thickening, and perivascular collagen deposition.
Long-Term Outpatient Management Principles
Management focuses on avoiding volume depletion and excessive cardiac demand, with therapy tailored to hypertrophy severity and distribution. Pharmacologic treatment includes beta-blockers or verapamil to slow heart rate and prolong diastole. Implantable cardioverter-defibrillators are indicated in patients with prior syncope, cardiac arrest, family history of sudden death, nonsustained ventricular tachycardia, abnormal blood pressure response to exercise, or massive hypertrophy. Septal reduction strategies include alcohol septal ablation and surgical septal myectomy, with improving outcomes at experienced centers.
Genetic Risk Profile
HCM was the first cardiac disease with an identified genetic basis (1989). It follows an autosomal-dominant inheritance pattern with more than 10 associated genes, most encoding sarcomeric proteins. Over 700 distinct mutations have been identified, with high penetrance and marked phenotypic variability. Some genotypes carry significantly higher risk of sudden death. Routine genotype-based risk stratification remains impractical due to complexity and incomplete understanding of modifier genes and environmental factors. Certain mutations involving cell membrane pumps are associated with increased arrhythmogenic risk.
Clinical Presentation
Symptoms often correlate with exertion or sudden upright posture, both of which reduce venous return and ventricular filling. Severity depends on hypertrophy location and extent. Common symptoms include exertional dyspnea, shortness of breath, postprandial or exertional angina, presyncope, syncope, congestive heart failure, cardiovascular collapse, and dysrhythmias. Paroxysmal atrial fibrillation may precipitate rapid deterioration, particularly in heart failure, and increases thromboembolic risk. Ventricular tachycardia or fibrillation may cause sudden death, while bradyarrhythmias are rare.
Patients may have a history of septal myectomy or alcohol ablation, with associated risks of conduction abnormalities or septal rupture. High-risk individuals may have implanted defibrillators. A family history of unexplained sudden death or known HCM is a critical diagnostic clue.
Pediatric Considerations
Disease severity may increase during adolescence. Any child with unexplained syncope, especially during exertion, warrants detailed family history (standard three-generation pedigree) and specialist referral.
Physical Examination Findings
Findings may be absent or subtle in nonobstructive disease. In obstructive HCM, findings may include a loud left-sided S4, a double apical impulse, and a crescendo–decrescendo midsystolic murmur best heard at the left sternal border. The murmur increases with standing or Valsalva and decreases with squatting, recumbency, or handgrip. Mitral regurgitation is common; radiation to the axilla suggests associated mitral insufficiency.
Electrocardiographic Features
ECG is abnormal in over 90% of patients. Findings include T-wave inversion >1 mm in multiple leads, ST-segment depression >0.5 mm, deep Q waves (>3 mm or >40 ms) excluding leads III and aVR, prolonged P waves with negative terminal forces in V1, and nonspecific intraventricular conduction delay >140 ms. Athletic ECG variants require careful interpretation, especially in non–African-Caribbean athletes over 16 years.
Laboratory and Imaging Evaluation
Routine laboratory testing has no diagnostic value in the emergency setting. Genetic testing is outpatient-focused. Chest radiography is usually normal but may show left ventricular free wall bulging, atrial enlargement, or pulmonary vascular redistribution. Transthoracic echocardiography with Doppler is the diagnostic cornerstone, demonstrating LV wall thickness >15 mm in adults (or ≥13–14 mm with supportive features), small or normal LV cavity, systolic outflow obstruction, and diastolic dysfunction. In children, wall thickness ≥2 standard deviations above the mean is diagnostic. Cardiac MRI supplements echocardiography, offering detailed assessment of hypertrophy distribution and fibrosis. Stress thallium and PET imaging may identify ischemia.
Differential Diagnosis
Consider vasovagal syncope, heat illness, aortic or pulmonic stenosis, ventricular septal defect, mitral regurgitation or prolapse, and coronary artery disease. Angina or heart failure in HCM carries higher risk than in non-HCM populations.
Emergency Management Principles
Suspect HCM in patients who deteriorate with standard heart failure, ischemia, or supraventricular tachycardia treatment, and in young athletes collapsing during exertion. Patients are highly sensitive to preload reduction and impaired diastolic filling. Initial management includes airway stabilization, oxygen, IV access, cardiac monitoring, and pulse oximetry. Patients may need to remain supine.
Avoid routine vasodilators for CHF or angina, as they may precipitate collapse. If hypotension occurs, administer cautious fluid boluses. Even mild hypovolemia can significantly reduce cardiac output. Rate control and improved diastolic filling are central goals. Beta-blockers are first-line therapy; verapamil is useful but nifedipine is relatively contraindicated due to vasodilation.
Supraventricular dysrhythmias are treated initially with beta-blockers or calcium channel blockers. Amiodarone is the drug of choice for ventricular dysrhythmias or refractory cases. Early electrical cardioversion is recommended for new-onset atrial fibrillation with heart failure.
Key Medications
Amiodarone, propranolol, verapamil, phenylephrine (for refractory hypotension without inotropic effect), and diltiazem (contraindicated in children under 12) may be used with careful hemodynamic assessment. All medications must be evaluated for their impact on outflow tract obstruction.
Disposition Decisions
Admission is required for unexplained syncope, heart failure, angina, or hemodynamically significant tachydysrhythmias, often to ICU level care. Discharge may be considered only when hypertrophy is an incidental finding without personal or family history of syncope or sudden death, with urgent cardiology follow-up arranged. Patients must be counseled to avoid exertion or situations that reduce preload until evaluated.
Clinical Pitfalls and Key Insights
Genetic and phenotypic diversity complicates diagnosis and risk stratification. Some advocate routine echocardiographic screening for youth sports participation or ICD placement at diagnosis. Any patient with syncope in whom HCM is suspected must be fully evaluated, as recurrence carries a high risk of sudden death.
Core Overview
Hypertrophic cardiomyopathy (HCM) is a genetic disorder of the cardiac sarcomere caused by numerous mutations, resulting in a hypertrophied, nondilated left ventricle (and rarely right ventricle) without another cause such as hypertension or aortic stenosis. Phenotypic expression is highly variable. Two major forms exist: nonobstructive HCM, accounting for approximately 75% of patients with an estimated annual mortality of ~1%, and obstructive hypertrophic cardiomyopathy (HOCM), accounting for ~25% with more severe disease and an estimated annual mortality of ~2%.
HCM can present at any age, from neonates to the elderly, but most cases manifest during childhood or adolescence, often coinciding with the pubertal growth spurt. Disease diagnosed at younger ages is typically more severe. A small subset progresses to reduced left ventricular systolic function later in life. Adult-onset presentations are not uncommon and are frequently misdiagnosed as asthma, COPD, deconditioning, or sleep apnea. Lethal ventricular arrhythmias are more common in younger patients, while supraventricular arrhythmias increase with age. Atrial fibrillation is common and often poorly tolerated. HCM is the most common cause of atraumatic sudden death in young athletes under 35 years of age. Prevalence is approximately 1 in 500 adults based on echocardiographic screening.
Structural and Pathophysiologic Features
Pathology is characterized by marked and irregular ventricular wall thickening with myofibrillar disarray and fibrin deposition, predominantly affecting the high-pressure left ventricle. Septal hypertrophy is usually more pronounced than free wall thickening. In obstructive disease, hypertrophy may regress if outflow obstruction is relieved. Some phenotypes demonstrate progressive wall thinning with age, typically following marked hypertrophy earlier in life. Diastolic stiffness leads to atrial dilation. Microvascular dysfunction occurs due to impaired vasodilation, intimal thickening, and perivascular collagen deposition.
Long-Term Outpatient Management Principles
Management focuses on avoiding volume depletion and excessive cardiac demand, with therapy tailored to hypertrophy severity and distribution. Pharmacologic treatment includes beta-blockers or verapamil to slow heart rate and prolong diastole. Implantable cardioverter-defibrillators are indicated in patients with prior syncope, cardiac arrest, family history of sudden death, nonsustained ventricular tachycardia, abnormal blood pressure response to exercise, or massive hypertrophy. Septal reduction strategies include alcohol septal ablation and surgical septal myectomy, with improving outcomes at experienced centers.
Genetic Risk Profile
HCM was the first cardiac disease with an identified genetic basis (1989). It follows an autosomal-dominant inheritance pattern with more than 10 associated genes, most encoding sarcomeric proteins. Over 700 distinct mutations have been identified, with high penetrance and marked phenotypic variability. Some genotypes carry significantly higher risk of sudden death. Routine genotype-based risk stratification remains impractical due to complexity and incomplete understanding of modifier genes and environmental factors. Certain mutations involving cell membrane pumps are associated with increased arrhythmogenic risk.
Clinical Presentation
Symptoms often correlate with exertion or sudden upright posture, both of which reduce venous return and ventricular filling. Severity depends on hypertrophy location and extent. Common symptoms include exertional dyspnea, shortness of breath, postprandial or exertional angina, presyncope, syncope, congestive heart failure, cardiovascular collapse, and dysrhythmias. Paroxysmal atrial fibrillation may precipitate rapid deterioration, particularly in heart failure, and increases thromboembolic risk. Ventricular tachycardia or fibrillation may cause sudden death, while bradyarrhythmias are rare.
Patients may have a history of septal myectomy or alcohol ablation, with associated risks of conduction abnormalities or septal rupture. High-risk individuals may have implanted defibrillators. A family history of unexplained sudden death or known HCM is a critical diagnostic clue.
Pediatric Considerations
Disease severity may increase during adolescence. Any child with unexplained syncope, especially during exertion, warrants detailed family history (standard three-generation pedigree) and specialist referral.
Physical Examination Findings
Findings may be absent or subtle in nonobstructive disease. In obstructive HCM, findings may include a loud left-sided S4, a double apical impulse, and a crescendo–decrescendo midsystolic murmur best heard at the left sternal border. The murmur increases with standing or Valsalva and decreases with squatting, recumbency, or handgrip. Mitral regurgitation is common; radiation to the axilla suggests associated mitral insufficiency.
Electrocardiographic Features
ECG is abnormal in over 90% of patients. Findings include T-wave inversion >1 mm in multiple leads, ST-segment depression >0.5 mm, deep Q waves (>3 mm or >40 ms) excluding leads III and aVR, prolonged P waves with negative terminal forces in V1, and nonspecific intraventricular conduction delay >140 ms. Athletic ECG variants require careful interpretation, especially in non–African-Caribbean athletes over 16 years.
Laboratory and Imaging Evaluation
Routine laboratory testing has no diagnostic value in the emergency setting. Genetic testing is outpatient-focused. Chest radiography is usually normal but may show left ventricular free wall bulging, atrial enlargement, or pulmonary vascular redistribution. Transthoracic echocardiography with Doppler is the diagnostic cornerstone, demonstrating LV wall thickness >15 mm in adults (or ≥13–14 mm with supportive features), small or normal LV cavity, systolic outflow obstruction, and diastolic dysfunction. In children, wall thickness ≥2 standard deviations above the mean is diagnostic. Cardiac MRI supplements echocardiography, offering detailed assessment of hypertrophy distribution and fibrosis. Stress thallium and PET imaging may identify ischemia.
Differential Diagnosis
Consider vasovagal syncope, heat illness, aortic or pulmonic stenosis, ventricular septal defect, mitral regurgitation or prolapse, and coronary artery disease. Angina or heart failure in HCM carries higher risk than in non-HCM populations.
Emergency Management Principles
Suspect HCM in patients who deteriorate with standard heart failure, ischemia, or supraventricular tachycardia treatment, and in young athletes collapsing during exertion. Patients are highly sensitive to preload reduction and impaired diastolic filling. Initial management includes airway stabilization, oxygen, IV access, cardiac monitoring, and pulse oximetry. Patients may need to remain supine.
Avoid routine vasodilators for CHF or angina, as they may precipitate collapse. If hypotension occurs, administer cautious fluid boluses. Even mild hypovolemia can significantly reduce cardiac output. Rate control and improved diastolic filling are central goals. Beta-blockers are first-line therapy; verapamil is useful but nifedipine is relatively contraindicated due to vasodilation.
Supraventricular dysrhythmias are treated initially with beta-blockers or calcium channel blockers. Amiodarone is the drug of choice for ventricular dysrhythmias or refractory cases. Early electrical cardioversion is recommended for new-onset atrial fibrillation with heart failure.
Key Medications
Amiodarone, propranolol, verapamil, phenylephrine (for refractory hypotension without inotropic effect), and diltiazem (contraindicated in children under 12) may be used with careful hemodynamic assessment. All medications must be evaluated for their impact on outflow tract obstruction.
Disposition Decisions
Admission is required for unexplained syncope, heart failure, angina, or hemodynamically significant tachydysrhythmias, often to ICU level care. Discharge may be considered only when hypertrophy is an incidental finding without personal or family history of syncope or sudden death, with urgent cardiology follow-up arranged. Patients must be counseled to avoid exertion or situations that reduce preload until evaluated.
Clinical Pitfalls and Key Insights
Genetic and phenotypic diversity complicates diagnosis and risk stratification. Some advocate routine echocardiographic screening for youth sports participation or ICD placement at diagnosis. Any patient with syncope in whom HCM is suspected must be fully evaluated, as recurrence carries a high risk of sudden death.
- Published on
Emergency and Acute Medicine – Cerebral Aneurysm
Core Overview
A cerebral aneurysm is a focal dilation or outpouching of a cerebral artery wall. It occurs in approximately 5–10% of the population. Rupture of saccular aneurysms accounts for 5–15% of all strokes. Distribution of ruptured aneurysms includes the anterior communicating artery (≈40%), internal carotid artery (≈30%), middle cerebral artery (≈20%), and vertebrobasilar system (≈5–10%).
Underlying Causes and Associations
Most cerebral aneurysms are saccular (berry) aneurysms, representing about 90% of cases. They develop at arterial bifurcations and weak points in vessel walls and increase in incidence with age. Multiple aneurysms occur in 20–30% of patients. Higher prevalence is seen with polycystic kidney disease, cerebral AVMs, connective tissue disorders (Ehlers–Danlos, Marfan), fibromuscular dysplasia, moyamoya syndrome, coarctation of the aorta, sickle cell disease, neurofibromatosis, and inflammatory or genetic disorders. Fusiform or dolichoectatic aneurysms account for about 7% and are more common in peripheral vessels. Mycotic aneurysms occur in roughly 10% of patients with bacterial endocarditis. Traumatic and neoplastic aneurysms are less common. A first-degree relative with an aneurysm nearly doubles lifetime risk. In children, aneurysms are rare but often large and located in the posterior circulation.
Clinical Presentation
Most aneurysms are asymptomatic until rupture. Sentinel headaches occur in 30–60% of patients and may precede rupture. Rupture leads to subarachnoid hemorrhage, typically presenting with a sudden, severe “thunderclap” headache described as the worst headache of life, often without focal deficits. Nuchal rigidity is common due to blood in the CSF. Seizures, syncope, or altered mental status may occur. Compression of adjacent structures can cause focal neurologic signs. ACA aneurysms may affect optic pathways, causing visual field deficits. Internal carotid–posterior communicating artery aneurysms often compress the oculomotor nerve, producing ptosis, diplopia, and a fixed dilated pupil. Cortical aneurysms may cause hemiparesis, aphasia, visual disturbances, or seizures.
Essential Evaluation
A complete neurologic examination is critical. Emergent noncontrast head CT detects 90–95% of subarachnoid hemorrhages. If CT is negative but suspicion remains high, lumbar puncture with CSF analysis is required.
Diagnostic Studies
Laboratory testing includes CBC, coagulation studies, electrolytes, renal and liver function tests, and arterial blood gas as indicated. Imaging includes chest radiography for pulmonary edema. Four-vessel cerebral angiography remains the diagnostic gold standard. CTA and MRA can identify aneurysms larger than 3 mm. Transcranial Doppler ultrasound is useful for monitoring vasospasm. Lumbar puncture is indicated when CT is normal but aneurysmal rupture is suspected.
Key Differentials
Consider arteriovenous malformation, intracranial hemorrhage (subdural, epidural, intracerebral), thromboembolic stroke, meningitis, encephalitis, migraine, optic neuritis, acute glaucoma, hypertensive encephalopathy, metabolic disturbances, sinusitis, and temporal arteritis.
Prehospital Priorities
Field neurologic assessment is valuable, including level of consciousness, speech, motor deficits, gait, and facial symmetry. Patients with suspected subarachnoid hemorrhage may require emergent airway protection and rapid transport to a facility with CT and ICU capabilities.
Initial Stabilization
Secure airway, breathing, and circulation. Provide supplemental oxygen and continuous cardiac and pulse oximetry monitoring. Rapid-sequence intubation may be necessary. Check blood glucose immediately in altered patients and correct hypoglycemia. Reverse anticoagulation when indicated. Control nausea and vomiting to prevent spikes in intracranial pressure. Treat seizures acutely with IV benzodiazepines and antiepileptics; routine seizure prophylaxis is not recommended.
Emergency Department Management
Early goals include prevention of rebleeding, vasospasm, and hydrocephalus. Management follows subarachnoid hemorrhage protocols. Early neurosurgical involvement is essential. Ventriculostomy may be required for intracranial pressure control and can reduce systemic hypertension.
Definitive Intervention
Timing of angiography and repair remains debated, though early intervention is favored to reduce rebleeding and vasospasm. Pediatric aneurysms carry a high hemorrhage risk and should be repaired early.
Pharmacologic Therapy
Blood pressure control is essential, commonly with labetalol or nicardipine. Nimodipine is used orally or via nasogastric tube to reduce vasospasm risk and should never be given intravenously. Antiemetics and stool softeners help prevent increases in intracranial pressure. Antiepileptics are used for active seizures.
Disposition and Follow-Up
All patients with aneurysmal subarachnoid hemorrhage require ICU admission. Symptomatic unruptured aneurysms warrant admission and urgent neurosurgical consultation due to high rupture risk. Incidentally discovered, asymptomatic aneurysms may be discharged with close neurosurgical follow-up. Annual rupture risk is approximately 1–2%, with treatment thresholds often considered in the 4–8 mm range.
Clinical Pearls and Pitfalls
A normal CT does not exclude subarachnoid hemorrhage—lumbar puncture is essential when suspicion persists. Vasospasm typically develops around day 3 after bleeding or surgery. Nimodipine reduces vasospasm-related morbidity but must never be administered intravenously. Avoid nitroprusside and nitroglycerin, as they can increase cerebral blood volume and intracranial pressure.
Core Overview
A cerebral aneurysm is a focal dilation or outpouching of a cerebral artery wall. It occurs in approximately 5–10% of the population. Rupture of saccular aneurysms accounts for 5–15% of all strokes. Distribution of ruptured aneurysms includes the anterior communicating artery (≈40%), internal carotid artery (≈30%), middle cerebral artery (≈20%), and vertebrobasilar system (≈5–10%).
Underlying Causes and Associations
Most cerebral aneurysms are saccular (berry) aneurysms, representing about 90% of cases. They develop at arterial bifurcations and weak points in vessel walls and increase in incidence with age. Multiple aneurysms occur in 20–30% of patients. Higher prevalence is seen with polycystic kidney disease, cerebral AVMs, connective tissue disorders (Ehlers–Danlos, Marfan), fibromuscular dysplasia, moyamoya syndrome, coarctation of the aorta, sickle cell disease, neurofibromatosis, and inflammatory or genetic disorders. Fusiform or dolichoectatic aneurysms account for about 7% and are more common in peripheral vessels. Mycotic aneurysms occur in roughly 10% of patients with bacterial endocarditis. Traumatic and neoplastic aneurysms are less common. A first-degree relative with an aneurysm nearly doubles lifetime risk. In children, aneurysms are rare but often large and located in the posterior circulation.
Clinical Presentation
Most aneurysms are asymptomatic until rupture. Sentinel headaches occur in 30–60% of patients and may precede rupture. Rupture leads to subarachnoid hemorrhage, typically presenting with a sudden, severe “thunderclap” headache described as the worst headache of life, often without focal deficits. Nuchal rigidity is common due to blood in the CSF. Seizures, syncope, or altered mental status may occur. Compression of adjacent structures can cause focal neurologic signs. ACA aneurysms may affect optic pathways, causing visual field deficits. Internal carotid–posterior communicating artery aneurysms often compress the oculomotor nerve, producing ptosis, diplopia, and a fixed dilated pupil. Cortical aneurysms may cause hemiparesis, aphasia, visual disturbances, or seizures.
Essential Evaluation
A complete neurologic examination is critical. Emergent noncontrast head CT detects 90–95% of subarachnoid hemorrhages. If CT is negative but suspicion remains high, lumbar puncture with CSF analysis is required.
Diagnostic Studies
Laboratory testing includes CBC, coagulation studies, electrolytes, renal and liver function tests, and arterial blood gas as indicated. Imaging includes chest radiography for pulmonary edema. Four-vessel cerebral angiography remains the diagnostic gold standard. CTA and MRA can identify aneurysms larger than 3 mm. Transcranial Doppler ultrasound is useful for monitoring vasospasm. Lumbar puncture is indicated when CT is normal but aneurysmal rupture is suspected.
Key Differentials
Consider arteriovenous malformation, intracranial hemorrhage (subdural, epidural, intracerebral), thromboembolic stroke, meningitis, encephalitis, migraine, optic neuritis, acute glaucoma, hypertensive encephalopathy, metabolic disturbances, sinusitis, and temporal arteritis.
Prehospital Priorities
Field neurologic assessment is valuable, including level of consciousness, speech, motor deficits, gait, and facial symmetry. Patients with suspected subarachnoid hemorrhage may require emergent airway protection and rapid transport to a facility with CT and ICU capabilities.
Initial Stabilization
Secure airway, breathing, and circulation. Provide supplemental oxygen and continuous cardiac and pulse oximetry monitoring. Rapid-sequence intubation may be necessary. Check blood glucose immediately in altered patients and correct hypoglycemia. Reverse anticoagulation when indicated. Control nausea and vomiting to prevent spikes in intracranial pressure. Treat seizures acutely with IV benzodiazepines and antiepileptics; routine seizure prophylaxis is not recommended.
Emergency Department Management
Early goals include prevention of rebleeding, vasospasm, and hydrocephalus. Management follows subarachnoid hemorrhage protocols. Early neurosurgical involvement is essential. Ventriculostomy may be required for intracranial pressure control and can reduce systemic hypertension.
Definitive Intervention
Timing of angiography and repair remains debated, though early intervention is favored to reduce rebleeding and vasospasm. Pediatric aneurysms carry a high hemorrhage risk and should be repaired early.
Pharmacologic Therapy
Blood pressure control is essential, commonly with labetalol or nicardipine. Nimodipine is used orally or via nasogastric tube to reduce vasospasm risk and should never be given intravenously. Antiemetics and stool softeners help prevent increases in intracranial pressure. Antiepileptics are used for active seizures.
Disposition and Follow-Up
All patients with aneurysmal subarachnoid hemorrhage require ICU admission. Symptomatic unruptured aneurysms warrant admission and urgent neurosurgical consultation due to high rupture risk. Incidentally discovered, asymptomatic aneurysms may be discharged with close neurosurgical follow-up. Annual rupture risk is approximately 1–2%, with treatment thresholds often considered in the 4–8 mm range.
Clinical Pearls and Pitfalls
A normal CT does not exclude subarachnoid hemorrhage—lumbar puncture is essential when suspicion persists. Vasospasm typically develops around day 3 after bleeding or surgery. Nimodipine reduces vasospasm-related morbidity but must never be administered intravenously. Avoid nitroprusside and nitroglycerin, as they can increase cerebral blood volume and intracranial pressure.
- Published on
Emergency and Acute Medicine – Cervical Adenitis
Overview
Cervical adenitis is an acute bacterial infection of a cervical lymph node, most often arising after a preceding bacterial infection of the head or neck. It is primarily a pediatric condition but is increasingly recognized in adults, particularly those who are immunocompromised (HIV, malignancy, transplant recipients). Any cervical node may be involved, though more than 80% of pediatric cases affect the submandibular or deep cervical nodes, commonly the jugulodigastric node just below the mandibular angle. Cervical lymph nodes serve as the final common drainage pathway for the head and neck. Initial lymphadenopathy reflects hyperplasia and lymphocytic infiltration; progression to lymphadenitis occurs when bacteria proliferate within the lymphatic system, leading to neutrophil activation, pus formation, abscess development, and a clinically warm, tender, erythematous, swollen node.
Causative Factors
Approximately 70% of cases are due to group A β-hemolytic Streptococcus, 20% to Staphylococcus aureus, and about 10% to viral or other bacterial causes. Community-acquired MRSA infections are increasingly common, particularly in children, who have high colonization and invasive disease rates. Mycobacterial causes include tuberculosis (scrofula), typically a chronic posterior cervical lymphadenitis with strongly positive PPD and nonsurgical management, and atypical mycobacteria such as Mycobacterium avium complex, which usually presents as chronic submandibular or anterior cervical lymphadenitis and is treated surgically. Bartonella henselae causes catscratch disease, a subacute lymphadenitis with minimal systemic symptoms that usually resolves spontaneously over 4–6 weeks. Anaerobes should be considered with dental or gingival infections. Rare pathogens include gram-negative bacilli, Yersinia pestis, group B Streptococcus, Francisella tularensis, alpha-streptococcus, and Bacillus anthracis.
In neonates, group B Streptococcus and S. aureus predominate. Group B streptococcal cellulitis–adenitis syndrome presents in infants 3–7 weeks old with fever, submandibular or facial cellulitis, ipsilateral otitis media, and a high rate of bacteremia. Viral infections often cause bilateral adenopathy. In older adults, malignancy should be considered, particularly with hard, fixed, nontender nodes and absence of systemic infection signs.
Clinical Presentation
Patients typically present with a unilateral, enlarged, tender cervical lymph node with overlying warmth and erythema. The node is initially firm and may become fluctuant as suppuration develops. Fever may be present, along with malaise, and irritability in infants and children. A concurrent head or neck infection is common, including pharyngitis, tonsillitis, peritonsillar abscess, otitis media or externa, dental infection, impetigo, or scalp infection.
History and Examination
Key history includes timing of onset, associated fever, weight loss or rash, exposure or travel history, and comorbidities or birth history in infants. Physical examination requires a complete head and neck assessment with attention to airway patency and overall clinical appearance.
Evaluation Strategy
Cervical adenitis is primarily a clinical diagnosis. Identification of a primary head or neck infection source is essential. If no local source is found, tuberculosis exposure should be considered and systemic or viral illness evaluated. Laboratory studies are unnecessary when a clear, treatable source is identified. Blood cultures are reserved for toxic-appearing patients, and full sepsis evaluation is required in neonates. When etiology is unclear, adjunct testing such as CBC with differential, Monospot, throat cultures, and targeted serologies (EBV, CMV, toxoplasmosis) may be useful. Imaging with chest radiograph, lateral neck film, or Panorex can help identify occult sources or deep space infection; chest radiograph may screen for tuberculosis. Ultrasound can distinguish cystic from solid lesions and detect deep abscesses, while CT or MRI helps delineate deep space infections or congenital masses. Fluctuant nodes should undergo needle aspiration for Gram stain, acid-fast stain, and aerobic, anaerobic, mycobacterial, and fungal cultures, except when tuberculosis is suspected, due to risk of sinus tract formation.
Alternative Diagnoses
Consider reactive lymphadenopathy from viral infections (adenovirus, rhinovirus, enterovirus, EBV, HSV, VZV, CMV), mumps, rubella, rubeola, Kawasaki disease, Kikuchi disease, PFAPA syndrome, toxoplasmosis, congenital cysts (branchial cleft, thyroglossal duct cyst, cystic hygroma), malignancy (leukemia, lymphoma, rhabdomyosarcoma, thyroid carcinoma), and systemic inflammatory diseases such as lupus or sarcoidosis.
Management Principles
Airway monitoring is essential if significant neck swelling is present. Treatment targets the underlying source of infection, with empiric coverage for group A Streptococcus and S. aureus; MRSA coverage should be considered if there is poor response to standard therapy. All fluctuant nodes require aspiration. Oral agents such as cephalexin, cefadroxil, or amoxicillin–clavulanate are commonly effective. Clindamycin or amoxicillin–clavulanate is preferred when dental or anaerobic sources are suspected. CA-MRSA may be treated with clindamycin or TMP-SMX, recognizing increasing resistance; toxic patients may require IV vancomycin or linezolid. Antibiotic therapy should continue for at least 10 days. Adjunctive measures include warm compresses and analgesia.
Disposition and Follow-Up
Admission is indicated for neonates, airway compromise, toxic appearance, immunocompromised patients, inability to tolerate oral intake, or failure of outpatient therapy. Most patients can be discharged on oral antibiotics with mandatory re-evaluation in 48–72 hours. Patients should return immediately for worsening symptoms, abscess formation, voice changes, dyspnea, or systemic illness. Referral to ENT or dentistry is based on the infection source, and concerning features for malignancy or congenital anomalies warrant specialist evaluation.
Clinical Insights
Cervical adenitis is a clinical diagnosis most often caused by group A Streptococcus or Staphylococcus aureus. Unilateral, warm, tender, erythematous lymphadenopathy is characteristic. Consider group B Streptococcus in young infants and MRSA in cases not improving with standard therapy. Disposition decisions should be guided by overall clinical status rather than node size alone.
Overview
Cervical adenitis is an acute bacterial infection of a cervical lymph node, most often arising after a preceding bacterial infection of the head or neck. It is primarily a pediatric condition but is increasingly recognized in adults, particularly those who are immunocompromised (HIV, malignancy, transplant recipients). Any cervical node may be involved, though more than 80% of pediatric cases affect the submandibular or deep cervical nodes, commonly the jugulodigastric node just below the mandibular angle. Cervical lymph nodes serve as the final common drainage pathway for the head and neck. Initial lymphadenopathy reflects hyperplasia and lymphocytic infiltration; progression to lymphadenitis occurs when bacteria proliferate within the lymphatic system, leading to neutrophil activation, pus formation, abscess development, and a clinically warm, tender, erythematous, swollen node.
Causative Factors
Approximately 70% of cases are due to group A β-hemolytic Streptococcus, 20% to Staphylococcus aureus, and about 10% to viral or other bacterial causes. Community-acquired MRSA infections are increasingly common, particularly in children, who have high colonization and invasive disease rates. Mycobacterial causes include tuberculosis (scrofula), typically a chronic posterior cervical lymphadenitis with strongly positive PPD and nonsurgical management, and atypical mycobacteria such as Mycobacterium avium complex, which usually presents as chronic submandibular or anterior cervical lymphadenitis and is treated surgically. Bartonella henselae causes catscratch disease, a subacute lymphadenitis with minimal systemic symptoms that usually resolves spontaneously over 4–6 weeks. Anaerobes should be considered with dental or gingival infections. Rare pathogens include gram-negative bacilli, Yersinia pestis, group B Streptococcus, Francisella tularensis, alpha-streptococcus, and Bacillus anthracis.
In neonates, group B Streptococcus and S. aureus predominate. Group B streptococcal cellulitis–adenitis syndrome presents in infants 3–7 weeks old with fever, submandibular or facial cellulitis, ipsilateral otitis media, and a high rate of bacteremia. Viral infections often cause bilateral adenopathy. In older adults, malignancy should be considered, particularly with hard, fixed, nontender nodes and absence of systemic infection signs.
Clinical Presentation
Patients typically present with a unilateral, enlarged, tender cervical lymph node with overlying warmth and erythema. The node is initially firm and may become fluctuant as suppuration develops. Fever may be present, along with malaise, and irritability in infants and children. A concurrent head or neck infection is common, including pharyngitis, tonsillitis, peritonsillar abscess, otitis media or externa, dental infection, impetigo, or scalp infection.
History and Examination
Key history includes timing of onset, associated fever, weight loss or rash, exposure or travel history, and comorbidities or birth history in infants. Physical examination requires a complete head and neck assessment with attention to airway patency and overall clinical appearance.
Evaluation Strategy
Cervical adenitis is primarily a clinical diagnosis. Identification of a primary head or neck infection source is essential. If no local source is found, tuberculosis exposure should be considered and systemic or viral illness evaluated. Laboratory studies are unnecessary when a clear, treatable source is identified. Blood cultures are reserved for toxic-appearing patients, and full sepsis evaluation is required in neonates. When etiology is unclear, adjunct testing such as CBC with differential, Monospot, throat cultures, and targeted serologies (EBV, CMV, toxoplasmosis) may be useful. Imaging with chest radiograph, lateral neck film, or Panorex can help identify occult sources or deep space infection; chest radiograph may screen for tuberculosis. Ultrasound can distinguish cystic from solid lesions and detect deep abscesses, while CT or MRI helps delineate deep space infections or congenital masses. Fluctuant nodes should undergo needle aspiration for Gram stain, acid-fast stain, and aerobic, anaerobic, mycobacterial, and fungal cultures, except when tuberculosis is suspected, due to risk of sinus tract formation.
Alternative Diagnoses
Consider reactive lymphadenopathy from viral infections (adenovirus, rhinovirus, enterovirus, EBV, HSV, VZV, CMV), mumps, rubella, rubeola, Kawasaki disease, Kikuchi disease, PFAPA syndrome, toxoplasmosis, congenital cysts (branchial cleft, thyroglossal duct cyst, cystic hygroma), malignancy (leukemia, lymphoma, rhabdomyosarcoma, thyroid carcinoma), and systemic inflammatory diseases such as lupus or sarcoidosis.
Management Principles
Airway monitoring is essential if significant neck swelling is present. Treatment targets the underlying source of infection, with empiric coverage for group A Streptococcus and S. aureus; MRSA coverage should be considered if there is poor response to standard therapy. All fluctuant nodes require aspiration. Oral agents such as cephalexin, cefadroxil, or amoxicillin–clavulanate are commonly effective. Clindamycin or amoxicillin–clavulanate is preferred when dental or anaerobic sources are suspected. CA-MRSA may be treated with clindamycin or TMP-SMX, recognizing increasing resistance; toxic patients may require IV vancomycin or linezolid. Antibiotic therapy should continue for at least 10 days. Adjunctive measures include warm compresses and analgesia.
Disposition and Follow-Up
Admission is indicated for neonates, airway compromise, toxic appearance, immunocompromised patients, inability to tolerate oral intake, or failure of outpatient therapy. Most patients can be discharged on oral antibiotics with mandatory re-evaluation in 48–72 hours. Patients should return immediately for worsening symptoms, abscess formation, voice changes, dyspnea, or systemic illness. Referral to ENT or dentistry is based on the infection source, and concerning features for malignancy or congenital anomalies warrant specialist evaluation.
Clinical Insights
Cervical adenitis is a clinical diagnosis most often caused by group A Streptococcus or Staphylococcus aureus. Unilateral, warm, tender, erythematous lymphadenopathy is characteristic. Consider group B Streptococcus in young infants and MRSA in cases not improving with standard therapy. Disposition decisions should be guided by overall clinical status rather than node size alone.
- Published on
Emergency and Acute Medicine – Cardiomyopathy
Foundational Overview
Cardiomyopathies are disorders of the myocardium associated with structural and functional cardiac impairment. Major forms include dilated cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, and unclassified variants. Specific cardiomyopathies occur secondary to systemic diseases or identifiable conditions. Dilated cardiomyopathy accounts for approximately 25% of all heart failure cases and is the most common subtype encountered in emergency care.
Causative Mechanisms
Dilated cardiomyopathy may be idiopathic, viral, genetic, toxic, immune mediated, or familial. Hypertrophic cardiomyopathy is typically an autosomal dominant inherited disorder. Restrictive cardiomyopathy may be idiopathic or related to infiltrative diseases such as amyloidosis. Arrhythmogenic right ventricular cardiomyopathy is usually familial with either dominant or recessive inheritance. Secondary cardiomyopathies include infectious causes such as viral myocarditis, Lyme disease, Chagas disease, and HIV; toxic causes such as alcohol, chemotherapeutic agents, and peripartum states; metabolic causes including hyperthyroidism, pheochromocytoma, and stress-induced (Takotsubo) cardiomyopathy; and systemic diseases such as lupus, scleroderma, neuromuscular disorders, and amyloidosis.
Pediatric-Specific Etiologies
In children, cardiomyopathy may be idiopathic or genetic, including inborn errors of metabolism, neuromuscular disease, malformation syndromes, and familial isolated cardiomyopathies. Acquired causes include nutritional deficiencies, electrolyte and endocrine disturbances, toxins, collagen vascular disease, immunologic disorders, malignancy, morbid obesity, myocarditis, pulmonary disease, Kawasaki disease, infections, radiation, congenital heart disease, and perinatal asphyxia.
Clinical Manifestations
History may reveal antecedent viral illness, chemotherapy exposure, HIV, Lyme disease, pregnancy, substance use, or systemic conditions such as hemochromatosis or sarcoidosis. Family history of sudden cardiac death is a critical clue. Symptoms include exertional dyspnea, dizziness, palpitations, near-syncope or syncope, ventricular arrhythmias, and congestive heart failure. Pediatric presentations may include irritability, hepatomegaly, generalized weakness, hypoglycemia, metabolic acidosis, hyperammonemia, cyanosis, encephalopathy, and dysmorphic features. Pregnancy-related cardiomyopathy should be considered separately.
Initial Assessment Priorities
Evaluation focuses on vital signs, cardiopulmonary examination, evidence of volume overload, abdominal organomegaly, peripheral edema, and signs of systemic disease such as rash or goiter. Rapid identification of decompensated heart failure, malignant arrhythmias, or shock is essential.
Diagnostic Evaluation
Laboratory studies include CBC, metabolic panel, liver and thyroid function tests, cardiac biomarkers, and BNP (levels >100 pg/mL support heart failure). Serologic testing is rarely helpful in the emergency setting. Chest radiography may demonstrate cardiomegaly, pulmonary congestion, and pleural effusions in dilated cardiomyopathy, whereas restrictive cardiomyopathy often shows a normal cardiac silhouette with pulmonary congestion. Emergency bedside transthoracic echocardiography may reveal depressed LV ejection fraction and exclude pericardial tamponade. Formal echocardiography is the diagnostic study of choice to characterize chamber size, wall thickness, systolic and diastolic function, and valvular disease. CT and cardiac MRI help differentiate restrictive cardiomyopathy from constrictive pericarditis and provide detailed assessment of myocardial anatomy, fibrosis, infiltration, iron overload, and viability.
Electrocardiographic Patterns
Hypertrophic cardiomyopathy commonly shows LV hypertrophy and deep Q waves in inferolateral leads, particularly in adolescents. Dilated, toxic, Lyme, and Chagas cardiomyopathies may present with atrial fibrillation, heart block, conduction delays, or pseudoinfarct patterns. Stress-induced (Takotsubo) cardiomyopathy may mimic STEMI and often necessitates cardiac catheterization to exclude ischemia.
Important Differentials
Other causes of dyspnea include COPD, asthma, anemia, interstitial lung disease, pulmonary embolism, pericardial tamponade, valvular disease, ischemic heart disease, hypothyroidism, and constrictive pericarditis. Syncope differentials include hypovolemia, hypoglycemia, heat illness, arrhythmia, and cardiac ischemia.
Prehospital Considerations
Patients require monitoring, supplemental oxygen, and cautious use of nitrates, particularly in suspected hypertrophic cardiomyopathy. Decompensated heart failure may benefit from nitrates and noninvasive positive-pressure ventilation.
Emergency Stabilization
Management prioritizes airway, breathing, and circulation with oxygen supplementation and noninvasive ventilation when indicated. Intubation is reserved for respiratory failure or severe encephalopathy.
Definitive Emergency Management
Treatment focuses on standard heart failure and arrhythmia protocols. Anticoagulation is indicated in dilated cardiomyopathy with atrial fibrillation or embolic risk. Atrial fibrillation and ventricular dysrhythmias are managed per ACLS principles. In hypertrophic cardiomyopathy, negative inotropes such as beta-blockers or disopyramide may reduce outflow obstruction. Special pediatric considerations include keeping patients NPO until inborn metabolic errors are excluded, administering dextrose-containing fluids cautiously, and avoiding lactate-containing solutions. Carnitine, antioxidants, and vitamin cofactors may be required in metabolic disorders.
Common Emergency Medications
Therapies may include amiodarone, beta-blockers, calcium channel blockers, diuretics, nitrates, anticoagulation, milrinone, nesiritide, and disease-specific agents such as carnitine, with careful age- and comorbidity-adjusted dosing.
Disposition Planning
Admission is required for new or suspected cardiomyopathy, syncope with concern for arrhythmia or hypertrophic cardiomyopathy, family history of sudden death, cardiogenic shock, or significant decompensation. Discharge may be considered for known cardiomyopathy with mild heart failure responding to treatment, typically after cardiology consultation.
Referral and Follow-Up
Patients with reduced ejection fraction (<35%) may require referral for implantable cardioverter-defibrillators, biventricular pacing, ventricular assist devices, or transplant evaluation. ongoing cardiology follow-up and consideration of genetic testing are essential.< />pan>
Clinical Insights
Bedside echocardiography is a powerful emergency tool in patients with syncope or exertional symptoms. A thorough family history is critical, as inherited cardiomyopathies are a major cause of sudden cardiac death in young patients.
Foundational Overview
Cardiomyopathies are disorders of the myocardium associated with structural and functional cardiac impairment. Major forms include dilated cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, and unclassified variants. Specific cardiomyopathies occur secondary to systemic diseases or identifiable conditions. Dilated cardiomyopathy accounts for approximately 25% of all heart failure cases and is the most common subtype encountered in emergency care.
Causative Mechanisms
Dilated cardiomyopathy may be idiopathic, viral, genetic, toxic, immune mediated, or familial. Hypertrophic cardiomyopathy is typically an autosomal dominant inherited disorder. Restrictive cardiomyopathy may be idiopathic or related to infiltrative diseases such as amyloidosis. Arrhythmogenic right ventricular cardiomyopathy is usually familial with either dominant or recessive inheritance. Secondary cardiomyopathies include infectious causes such as viral myocarditis, Lyme disease, Chagas disease, and HIV; toxic causes such as alcohol, chemotherapeutic agents, and peripartum states; metabolic causes including hyperthyroidism, pheochromocytoma, and stress-induced (Takotsubo) cardiomyopathy; and systemic diseases such as lupus, scleroderma, neuromuscular disorders, and amyloidosis.
Pediatric-Specific Etiologies
In children, cardiomyopathy may be idiopathic or genetic, including inborn errors of metabolism, neuromuscular disease, malformation syndromes, and familial isolated cardiomyopathies. Acquired causes include nutritional deficiencies, electrolyte and endocrine disturbances, toxins, collagen vascular disease, immunologic disorders, malignancy, morbid obesity, myocarditis, pulmonary disease, Kawasaki disease, infections, radiation, congenital heart disease, and perinatal asphyxia.
Clinical Manifestations
History may reveal antecedent viral illness, chemotherapy exposure, HIV, Lyme disease, pregnancy, substance use, or systemic conditions such as hemochromatosis or sarcoidosis. Family history of sudden cardiac death is a critical clue. Symptoms include exertional dyspnea, dizziness, palpitations, near-syncope or syncope, ventricular arrhythmias, and congestive heart failure. Pediatric presentations may include irritability, hepatomegaly, generalized weakness, hypoglycemia, metabolic acidosis, hyperammonemia, cyanosis, encephalopathy, and dysmorphic features. Pregnancy-related cardiomyopathy should be considered separately.
Initial Assessment Priorities
Evaluation focuses on vital signs, cardiopulmonary examination, evidence of volume overload, abdominal organomegaly, peripheral edema, and signs of systemic disease such as rash or goiter. Rapid identification of decompensated heart failure, malignant arrhythmias, or shock is essential.
Diagnostic Evaluation
Laboratory studies include CBC, metabolic panel, liver and thyroid function tests, cardiac biomarkers, and BNP (levels >100 pg/mL support heart failure). Serologic testing is rarely helpful in the emergency setting. Chest radiography may demonstrate cardiomegaly, pulmonary congestion, and pleural effusions in dilated cardiomyopathy, whereas restrictive cardiomyopathy often shows a normal cardiac silhouette with pulmonary congestion. Emergency bedside transthoracic echocardiography may reveal depressed LV ejection fraction and exclude pericardial tamponade. Formal echocardiography is the diagnostic study of choice to characterize chamber size, wall thickness, systolic and diastolic function, and valvular disease. CT and cardiac MRI help differentiate restrictive cardiomyopathy from constrictive pericarditis and provide detailed assessment of myocardial anatomy, fibrosis, infiltration, iron overload, and viability.
Electrocardiographic Patterns
Hypertrophic cardiomyopathy commonly shows LV hypertrophy and deep Q waves in inferolateral leads, particularly in adolescents. Dilated, toxic, Lyme, and Chagas cardiomyopathies may present with atrial fibrillation, heart block, conduction delays, or pseudoinfarct patterns. Stress-induced (Takotsubo) cardiomyopathy may mimic STEMI and often necessitates cardiac catheterization to exclude ischemia.
Important Differentials
Other causes of dyspnea include COPD, asthma, anemia, interstitial lung disease, pulmonary embolism, pericardial tamponade, valvular disease, ischemic heart disease, hypothyroidism, and constrictive pericarditis. Syncope differentials include hypovolemia, hypoglycemia, heat illness, arrhythmia, and cardiac ischemia.
Prehospital Considerations
Patients require monitoring, supplemental oxygen, and cautious use of nitrates, particularly in suspected hypertrophic cardiomyopathy. Decompensated heart failure may benefit from nitrates and noninvasive positive-pressure ventilation.
Emergency Stabilization
Management prioritizes airway, breathing, and circulation with oxygen supplementation and noninvasive ventilation when indicated. Intubation is reserved for respiratory failure or severe encephalopathy.
Definitive Emergency Management
Treatment focuses on standard heart failure and arrhythmia protocols. Anticoagulation is indicated in dilated cardiomyopathy with atrial fibrillation or embolic risk. Atrial fibrillation and ventricular dysrhythmias are managed per ACLS principles. In hypertrophic cardiomyopathy, negative inotropes such as beta-blockers or disopyramide may reduce outflow obstruction. Special pediatric considerations include keeping patients NPO until inborn metabolic errors are excluded, administering dextrose-containing fluids cautiously, and avoiding lactate-containing solutions. Carnitine, antioxidants, and vitamin cofactors may be required in metabolic disorders.
Common Emergency Medications
Therapies may include amiodarone, beta-blockers, calcium channel blockers, diuretics, nitrates, anticoagulation, milrinone, nesiritide, and disease-specific agents such as carnitine, with careful age- and comorbidity-adjusted dosing.
Disposition Planning
Admission is required for new or suspected cardiomyopathy, syncope with concern for arrhythmia or hypertrophic cardiomyopathy, family history of sudden death, cardiogenic shock, or significant decompensation. Discharge may be considered for known cardiomyopathy with mild heart failure responding to treatment, typically after cardiology consultation.
Referral and Follow-Up
Patients with reduced ejection fraction (<35%) may require referral for implantable cardioverter-defibrillators, biventricular pacing, ventricular assist devices, or transplant evaluation. ongoing cardiology follow-up and consideration of genetic testing are essential.< />pan>
Clinical Insights
Bedside echocardiography is a powerful emergency tool in patients with syncope or exertional symptoms. A thorough family history is critical, as inherited cardiomyopathies are a major cause of sudden cardiac death in young patients.
